

ARTHRITIS & RHEUMATISM

OFFICIAL JOURNAL OF THE AMERICAN RHEUMATISM ASSOCIATION
SECTION OF THE ARTHRITIS FOUNDATION

CONTENTS VOLUME 21, 1978

VOL. 21	JANUARY-FEBRUARY	No. 1
Radiographic Abnormalities of Rheumatoid Arthritis in Patients with Diffuse Idiopathic Skeletal Hyperostosis <i>Donald Resnick, John Curd, Robert F. Shapiro, and Kenneth B. Wiesner</i>	1	
Migrainous Phenomena in Systemic Lupus Erythematosus <i>Kenneth D. Brandt and Simmons Lessell</i>	7	
Direct Evidence for Circulating DNA/Anti-DNA Complexes in Systemic Lupus Erythematosus <i>John S. Davis, Stephania M. Godfrey, and John B. Winfield</i>	17	
Comparative Studies of Antilymphocyte, Antipolynucleotide, and Antiviral Antibodies among Families of Patients with Systemic Lupus Erythematosus <i>O. Folomeeva, V. A. Nassonova, A. S. Alekberova, N. Talal, and R. C. Williams, Jr.</i>	23	
Homozygous C2 Deficiency with Fulminant Lupus Erythematosus: Severe Nephritis via the Alternative Complement Pathway <i>Anita Gewurz, Thomas F. Lint, Jimmy L. Roberts, Howard Zeitz, and Henry Gewurz</i>	28	
Computer Analysis of Factors Influencing Frequency of Infection in Systemic Lupus Erythematosus <i>Ellen Ginzler, Herbert Diamond, David Kaplan, Max Weiner, Michael Schlesinger, and Mitchel Seleznick</i>	37	
Effect of Systemic Lupus Erythematosus Antibodies against DNA on RNA Synthesis <i>Olga V. Makarova</i>	45	
Impaired Immunoglobulin Synthesis by Peripheral Blood Lymphocytes in Systemic Lupus Erythematosus <i>Kenneth M. Nies and James S. Louie</i>	51	
Oral Mucosal Ulceration in Systemic Lupus Erythematosus <i>Jeffrey D. Urman, Mitchell B. Lowenstein, Micha Abeles, and Arthur Weinstein</i>	58	
Muscle Disease in Progressive Systemic Sclerosis: Diagnostic and Therapeutic Considerations <i>Philip J. Clements, Daniel E. Furst, David S. Campion, Anthony Bohan, Robert Harris, Joshua Levy, and Harold E. Paulus</i>	62	
Association between HLA-BW38 and Peripheral Psoriatic Arthritis <i>L. R. Espinoza, F. B. Vasey, J. H. Oh, R. Wilkinson, and C. K. Osterland</i>	72	
Fat Droplets and Synovial Fluid Leukocytosis in Traumatic Arthritis <i>Jimmy Graham and John A. Goldman</i>	76	
Pathogenesis of Chronic Inflammation in Experimental Ferritin-Induced Arthritis. IV. Immuno-Electron Microscopic Techniques in the Study of Articular Collagenous Tissues <i>Osamu Ohno, Hiroomi Tateishi, and T. Derek Cooke</i>	81	
Intratendon Sheath Corticosteroid Treatment of Rheumatoid Arthritis-Associated and Idiopathic Hand Flexor Tenosynovitis <i>Robert G. Gray, Iris M. Kiem, and Norman L. Gottlieb</i>	92	
Susceptibility of Rheumatoid and Nonrheumatoid Synovial Cells to Antibody-Dependent Cell-Mediated Cytotoxicity <i>Marie M. Griffiths, Charles B. Smith, and Barbara J. Pepper</i>	97	
Kinetic Studies of Phagocytosis. I. The Serum Independent Particle Uptake by PMN from Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus <i>R. Häggren, L. Häkansson, and P. Venge</i>	107	

Drugs Affecting the Release of Rheumatoid Factor in a Plaque-Forming Cell Assay <i>Terry L. Moore, Dick L. Robbins, Jean E. Rose, and John H. Vaughan</i>	114
Serum Antiimmunoglobulins Reactive with Human and Rabbit IgG in Rheumatoid Arthritis and Other Conditions <i>Diana J. Stankaitienė, Alfonsas A. Matulis, Henrikas Guobys, and Janina P. Jusėnaitė</i>	120
Micromeasurement of Plasma Salicylate in Arthritic Children <i>Jerry C. Jacobs and Michael Pesce</i>	129
Methyl Ester of N-Formylmethionyl-Leucyl-Phenylalanine: Chemotactic Responses of Human Blood Monocytes and Inhibition of Gold Compounds <i>Peter P. K. Ho, Anna L. Young, and George L. Southard</i>	133
Case Report: Proliferative Synovitis in Hemophilia: Biochemical and Morphologic Observations <i>Carlo L. Mainardi, Peter H. Levine, Zena Werb, and Edward D. Harris, Jr.</i>	137
Case Report: Shoulder Swelling in Rheumatoid Arthritis Secondary to Subacromial Bursitis <i>Kent A. Huston, Audrey M. Nelson, and Gene G. Hunder</i>	145
Case Report: Hemarthrosis as the Presenting Manifestation of True Myeloma Joint Disease <i>Gregorio Mintz, Elsa J. Robles-Saavedra, Rubén D. Enríquez, F. Javier Jiménez, and Ma. Lourdes Juán</i>	148
Editorial: Future Research Directions <i>J. Claude Bennett</i>	152
Future Research Directions: Amyloidosis: Current Trends in its Investigation <i>Alan S. Cohen, Edgar S. Cathcart, and Martha Skinner</i>	153
Radiologic Vignette No. 2: The Diagnostic Value of Buttressing of the Femoral Neck <i>William Martel and Ethan M. Braunstein</i>	161
Government Affairs <i>Roland W. Moskowitz</i>	165
Letters	167
Book Reviews	175
ARA Announcements	176

VOL. 21

MARCH

No. 2

Neoantigen of the Membrane Attack Complex of Human Complement: Occurrence on Peripheral Blood Leukocytes from Patients with Systemic Lupus Erythematosus <i>John G. Curd, John S. Sundsmo, William P. Kolb, Harry G. Bluestein, and Hans J. Müller-Eberhard</i>	177
Familial Lupus: Family Studies of HLA and Serologic Findings <i>Leslie G. Cleland, David A. Bell, Martin Willens, and Bruce C. Saurino</i>	183
Normal Distribution of Acetylation Phenotypes in Systemic Lupus Erythematosus <i>Johnathan Vansant, Raymond L. Woosley, J. Thomas John, and John S. Sergent</i>	192
Effect of Altered Lymphocyte Function on Immunologic Disorders in NZB/NZW Mice. III. Acceleration of Disease by Thymosin <i>Jagdish Mehta, Linda Knotts, Carolyn Craig, Sharon Burkholder, Christine Miller, and Bevra Hahn</i>	196
Therapeutic Studies in NZB/NZW Mice. VI. Age-Dependent Effects of Concanavalin A Stimulated Spleen Cell Supernate <i>Alfred D. Steinberg, Randall Krakauer, James L. Reinertsen, Lynell W. Klassen, David Ilfeld, J. Patton Reeves, Gary W. Williams, and Tatiana Antonovich</i>	204
Hand Structure and Function in an Industrial Setting: Influence of Three Patterns of Stereotyped, Repetitive Usage <i>Nortin M. Hadler, Dennis B. Gillings, Harold R. Imbus, Peter M. Levitin, Diane Makuc, Peter D. Utsinger, William J. Yount, Derwood Slusser, and Nancy Moskovitz</i>	210
Carpal Tunnel Syndrome with Polymyalgia Rheumatica <i>Tahir Ahmed and Alan I. Braun</i>	221
Automated Rheumatoid Factor Assay in a Population of Patients with Rheumatic Disease <i>Eric P. Gall, David W. Templin, and William R. Dito</i>	224
Psychosocial Factors in Juvenile Rheumatoid Arthritis <i>Monica Jean Henoch, Jean W. Batson, and John Baum</i>	229

Quantitative Sacroiliac Scintigraphy in Patients with Crohn's Disease Paul Davis, Alan B. R. Thomson, and Brian C. Lente	234
Hyporesponsiveness of Lymphocytes to Virus Antigens in Rheumatoid Arthritis Robert E. Wolf	238
Demonstration of Anticollagen Antibodies in Rheumatoid Arthritis Synovial Fluids by ^{14}C -Radioimmunoassay Johannes Menzel, Carl Steffen, Gernot Kolarz, Marina Kojer, and Josef Smolen	243
Immunopathologic Studies of Rheumatoid Arthritis. I. Absence of Complement-Dependent Cytotoxicity of Rheumatoid Sera for Rheumatoid Synovial Cell Cultures Stephen A. Paget, Karen Anderson, and Paul E. Phillips	249
Thrombocytosis and Platelet Aggregates in the Circulation of Adjuvant Arthritic Rats Peter Görög and Iren B. Kovács	256
Arthritis Rounds: Multiple Myeloma Complicating the Course of Seronegative Systemic Lupus Erythematosus Edward Jordan, Stephen L. Burnstein, John J. Calabro, and Edward S. Henderson	260
Discussion: Charles L. Christian	264
Current Comment: Type C Viruses and Systemic Lupus Erythematosus Joseph A. Markenson and Paul E. Phillips	266
Case Report: Vertebral Sarcoidosis with Paravertebral Ossification Susan G. Perlman, John Damergis, Phillip Witorsch, F. Donald Cooney, Stephen F. Gunther, and Werner F. Barth	271
Editorial	277
Letters	279
Book Reviews	285
ARA Announcements	287

VOL. 21

APRIL

No. 3

Serologic Studies in Patients with Systemic Lupus Erythematosus and Central Nervous System Dysfunction John B. Winfield, Carolyn M. Brunner, and David Koffer	289
Lymphopenia in Systemic Lupus Erythematosus: Clinical, Diagnostic, and Prognostic Significance Santiago J. Rivero, Efraim Diaz-Jouanen, and Donato Alarcón-Segovia	295
Monozygotic Twins with Klinefelter's Syndrome Discordant for Systemic Lupus Erythematosus and Symptomatic Myasthenia Gravis Joseph P. Michalski, Steven M. Snyder, Rima L. McLeod, and Norman Talal	306
Comparison of the Presence of Immune Complexes in Felty's Syndrome and Rheumatoid Arthritis Mario Andreis, Eric R. Hurd, Joseph Lospalluto, and Morris Ziff	310
Studies of the Effects of Pregnancy Serum on Polymorphonuclear Leukocyte Functions Robert H. Persellin and June K. Leibfarth	316
Decreased Lymphocyte Response to PHA, Con-A, and Calcium Ionophore (A23187) in Patients with RA and SLE, and Reversal with Levamisole in Rheumatoid Arthritis Morton A. Scheinberg, Leonilda Santos, Nelson F. Mendes, and Chloé Musatti	326
Synthesis by an Established Lymphocyte Cell Line from a Rheumatoid Synovium Bruce C. Gilliland, Denys K. Ford, and Mart Mannik	330
Relationship of HLA-Dw3 and HLA-B8 to Sjögren's Syndrome Kenneth H. Fye, Paul I. Terasaki, Joseph P. Michalski, Troy E. Daniels, Gerhard Opelz, and Norman Talal	337
Fibrinogen Turnover in Progressive Systemic Sclerosis Geoffrey M. Gratwick, Ronald Klein, John S. Sergent, and Charles L. Christian	343
Rapid Assessment of $^{99\text{m}}\text{Tc}$ -Pertechnetate Uptake in the Knee Joint as a Parameter of Inflammatory Activity Agnes M. TH. Boerbooms and Wil C. A. M. Buys	348
Immunoglobulin in Tophi and on the Surface of Monosodium Urate Crystals Peter Hasselbacher and H. Ralph Schumacher	353
Non-Giant Cell Temporal Arteritis: Three Cases and a Review of the Literature G. James Morgan, Jr. and Edward D. Harris, Jr.	362

Idiopathic Multicentric Osteolysis: Report of an Affected Father and Son Michael P. Whyte, William A. Murphy, Michael Kleerekoper, Steven L. Teitelbaum, and Louis V. Avioli	367
Current Comment: Prevalence of Rheumatic Diseases as Causes of Disability and Complaints by Ambulatory Patients Michael D. Reynolds	377
Arthritis Rounds: Ankylosing Spondylitis with Subsequent Development of Rheumatoid Arthritis, Sjögren's Syndrome, and Rheumatoid Vasculitis Michael D. Clayman and James L. Reinertsen	383
Discussion E. G. L. Bywaters	388
Letters	390
Book Reviews	398
ARA Announcements	400

VOL. 21

MAY

NO. 4

Total Hip Replacement in Children with Arthritis B. H. Singsen, A. S. Isaacson, B. H. Bernstein, M. J. Patzakis, H. K. Kornreich, K. K. King, and V. Hanson	401
Analysis of DNA Structure by Hydroxyapatite Columns and Ethidium Bromide Fluorescence Techniques: A Comparative Study and Effect on DNA Binding Paul Davis, Michael Burrrington, Anthony S. Russell, and A. Richard Morgan	407
Effect of the Anti-Estrogen, Nafoxidine, on NZB/W Autoimmune Disease Madeleine Duvic, Alfred D. Steinberg, and Lynell W. Klassen	414
Collagen in the Cellular and Fibrotic Stages of Scleroderma Raul Fleischmajer, Steffan Gay, Wilhelm N. Meigel, and Jerome S. Perlish	418
Pathologic Features of a Familial Arthropathy Associated with Congenital Flexion Contractures of Fingers Balu H. Athreya and H. Ralph Schumacher	429
Light Chain Heterogeneity of 19S and 7S Anti- γ -Globulins in Rheumatoid Arthritis and Subacute Bacterial Endocarditis Dennis A. Carson and Simon Lawrence	438
Comparison of Gold Levels and Distribution in Guinea Pig Serum H. Kamel, D. H. Brown, J. M. Ottaway, W. E. Smith, J. Cottney, and A. J. Lewis	441
Inorganic Pyrophosphatase Activity of the Synovial Fluid: Kinetic and Clinical Study Sergio Jacobelli, Ana Maria Kettlun, and Mario Sapag-Hagar	447
Enhancement of Urate Solubility by Connective Tissue. I. Effect of Proteoglycan Aggregates and Buffer Cation Elaine Perricone and Kenneth D. Brandt	453
The Growth Kinetics of Synovial Fibroblastic Cells from Inflammatory and Noninflammatory Arthropathies Tassos P. Anastassiades, Janice Ley, Anne Wood, and David Irwin	461
Vertebral Ankylosing Hyperostosis (Forestier's Disease) and HLA Antigens in Pima Indians Alan M. Spagnola, Peter H. Bennett, and Paul I. Terasaki	467
Age, Sex, and Race Effects on Mortality from Systemic Lupus Erythematosus in the United States Richard A. Kaslow and Alfonse T. Masi	473
Current Comment: Sex Effects in Systemic Lupus Erythematosus: A Clue to Pathogenesis Alfonse T. Masi and Richard A. Kaslow	480
Radiologic Vignette No. 3: Spinal Pseudoarthrosis: A Complication of Ankylosing Spondylitis William Martel	485
Letters	491

VOL. 21

JUNE

No. 5

Clinical Features of the Arthritis of Mixed Connective Tissue Disease <i>James T. Halla and Joe G. Hardin</i>	497
Autoimmune Neutropenia in Systemic Lupus Erythematosus <i>Gordon Starkebaum, Thomas H. Price, Minako Y. Lee, and William P. Arend</i>	504
Chryotherapy in Psoriatic Arthritis: Efficacy and Toxicity Compared to Rheumatoid Arthritis <i>Bonnie B. Dorwart, Eric P. Gall, H. Ralph Schumacher, and Ronald E. Krauser</i>	513
Electron Microscopic Morphology of Immunoglobulin Aggregates and Their Interactions in Rheumatoid Articular Collagenous Tissues <i>Osamu Ohno and T. Derek Cooke</i>	516
A Subgroup of Ankylosing Spondylitis Associated with HLA-B7 in American Blacks <i>Muhammad A. Khan, Irving Kushner, and William E. Braun</i>	528
Future Research Directions: The Infectious Etiology of Rheumatoid Arthritis: New Considerations <i>J. Claude Bennett</i>	531
Proceedings of the 42nd Annual Meeting of the American Rheumatism Association: Abstracts of Papers Presented	539
Letters	607
Books Received	614
ARA Announcements	615

VOL. 21

JUNE

No. 5 SUPPLEMENT

Proceedings of the Conference on New Directions for Research in Systemic Lupus Erythematosus	S1-S240
--	---------

VOL. 21

JULY-AUGUST

NO. 6

Introduction to the Joseph J. Bunim Memorial Lecture <i>Colon H. Wilson, Jr.</i>	617
Joseph J. Bunim Memorial Lecture: Seronegative Polyarthritides: A Unified Concept <i>V. Wright</i>	619
Studies on Heterophile Antibodies in Rheumatoid Arthritis <i>Tomoe Nishimaki, Kyoichi Kano, and Felix Milgrom</i>	634
Studies on Immune Complexes in Rheumatoid Arthritis <i>Tomoe Nishimaki, Kyoichi Kano, and Felix Milgrom</i>	639
A Controlled Study of ANA+ RF- Arthritis <i>Julius E. Linn, Joe G. Hardin, and James T. Halla</i>	645
A Study of HLA Antigens in Adults with Acute Rheumatic Fever <i>Garvin C. Murray, Milka M. Monteil, and Robert H. Persellin</i>	652
Studies of Immune Functions of Patients with Systemic Lupus Erythematosus. I. Dysfunction of Suppressor T-Cell Activity Related to Impaired Generation of, Rather than Response to, Suppressor Cells <i>Tsuyoshi Sakane, Alfred D. Steinberg, and Ira Green</i>	657
Androgenic Status of Males with Systemic Lupus Erythematosus <i>Neil I. Stahl and John L. Decker</i>	665
Horizontal Splitting in Patellar Articular Cartilage <i>G. Meachim and G. Bentley</i>	669
Antigen-Induced Arthritis: Decreased Proteoglycan Content and Inhibition of Proteoglycan Synthesis in Articular Cartilage <i>Dennis A. Lowther, John D. Sandy, Vivien B. Santer, and Heather L. G. Brown</i>	675

Hematologic and Serologic Studies in 6-Sulfanilamidoindazole Arthritis Morgan L. Miller, Cecil O. Samuelson, and John R. Ward	681
Mixed Lymphocyte Reaction in Healthy Women with Rheumatoid Factor: Lack of Association with HLA-Dw4 Edgar Engleman, Ernest E. Sponzilli, Marion E. Batey, Savitri Ramcharan, and Hugh O. McDevitt.....	690
Interrelationship between Stimulation of Prostaglandin E and Hyaluronate Production by Poly (I)·Poly (C) and Interferon in Synovial Fibroblast Culture Michael Yaron, Ilana Yaron, Chana Wiletzki, and Uriel Zor	694
The Amyloidosis of Juvenile Rheumatoid Arthritis—Comparative Studies in Polish and American Children. I. Levels of Serum SAA Protein Anna Maria Filipowicz-Sosnowska, Katarzyna Roztropowicz-Denisiewicz, C. Julian Rosenthal, and John Baum	699
Ocular Chrysiasis Correlated with Gold Concentrations in the Crystalline Lens during Chrysotherapy Norman L. Gottlieb and James C. Major	704
Mixed Connective Tissue Disease in Siblings John R. Horn, Janet J. Kapur, and Sara E. Walker	709
Atypical Axial Osteomalacia: Report of Four Cases with Two Having Features of Ankylosing Spondylitis A. M. Nelson, B. L. Riggs, and J. O. Jowsley	715
Case Report: Idiopathic Charcot Joint of the Elbow A. T. Blanford, S. P. Keane, D. J. McCarty, and J. W. Albers	723
Current Comment: The Satellite Arthritis Clinic Robert S. Pinals.....	727
Arthritis Rounds: Marrow Aplasia Induced by Colchicine: A Case Report Yong K. Liu, Richard Hymowitz, and Michael G. Carroll	731
Discussion Stephen E. Malawista	735
Letters	737
ARA Announcements.....	743

VOL. 21

SEPTEMBER-OCTOBER

NO. 7

Collagenase Production by Cultures Containing Multinucleated Cells Derived from Synovial Fibroblasts Constance E. Brinckerhoff and Edward D. Harris, Jr.	745
Boundary Lubricating Ability of Synovial Fluid in Degenerative Joint Disease Warren H. Davis, Jr., S. L. Lee, and Leon Sokoloff.....	754
Correlation between Articular Cartilage Collagenase Activity and Osteoarthritis Michael G. Ehrlich, Patricia A. Houle, Gloria Vigliani, and Henry J. Mankin.....	761
Differential Effects of Propranolol on Lymphocyte Rosette Formation and Response to Plant Mitogens James V. Dunne, Clarence J. Peters, Terry L. Moore, and John H. Vaughan.....	767
Synovial Fluid Lactic Acid: A Diagnostic Aid in Septic Arthritis Itzhak Brook, Michael J. Reza, Kenneth S. Bricknell, Rodney Bluestone, and Sydney M. Finegold.....	774
Temporal Arteriography: Analysis of 21 Cases and a Review of the Literature Lawrence F. Layfer, Barbara F. Banner, Michael S. Huckman, Lorne S. Grainer, and Harvey E. Golden	780
Chrysotherapy: Suppression of Immunoglobulin Synthesis Arthur Lorber, Timothy Simon, John Leeb, Alan Peter, and Stuart Wilcox.....	785
Effect of Inherited Deficiency of the Fifth Component of Complement on Arthritis Induced in Mice by <i>Mycoplasma Pulmonis</i> E. Keystone, D. Taylor-Robinson, C. Pope, G. Taylor, and P. Furr.....	792
Herpes Zoster in Patients with Systemic Lupus Erythematosus Haralampos M. Moutsopoulos, John D. Gallagher, John L. Decker, and Alfred D. Steinberg.....	798
Identification and Characterization of Two New Soluble Nuclear Antigens Reactive with Sera of Patients with Connective Tissue Diseases Shoji Miyawaki, Kiichi Kohmoto, Noriyuki Kurata, and Tadashi Ofuji.....	803
Gastrointestinal Systemic Sclerosis in Serologic Mixed Connective Tissue Disease Daniel A. Norman and Roy M. Fleischmann	811

Relative Reactivities of Rheumatoid Factors in Serum and Cells: Evidence for a Selective Deficiency in Serum Rheumatoid Factor <i>Dick L. Robbins, Terry L. Moore, Dennis A. Carson, and John H. Vaughan</i>	820
The Costs of Rheumatoid Arthritis: A Patient-Oriented Study of Chronic Disease Costs <i>Robert F. Meenan, Edward H. Yelin, Curtis J. Henke, David L. Curtis, and Wallace V. Epstein</i>	827
Case Report: Regional Migratory Osteoporosis: A Denervation Disease <i>W. Clay McCord, Kenneth M. Nies, David S. Campion, and James S. Louie</i>	834
Case Report: Central Retinal Vein Occlusion Complicating Systemic Lupus Erythematosus <i>Michael Silverman, Marvin J. Lubeck, and Walter G. Briney</i>	839
Case Report: Hemochromatotic Arthropathy Mimicking Rheumatoid Arthritis: A Case with Subcutaneous Nodules, Tenosynovitis, and Bursitis <i>William G. Bensen, Carl A. Laskin, Hugh A. Little, and Adel G. Fam</i>	844
Current Comment: Immunologic Sex Differences and the Female Predominance in Systemic Lupus Erythematosus <i>Robert D. Inman</i>	849
Future Research Directions: Autoimmunity and the Immunologic Network <i>Norman Talal</i>	853
Letters.....	862
Book Reviews.....	870
Books Received.....	871
ARA Announcements.....	872

Vol. 21

NOVEMBER-DECEMBER

No. 8

Reactivities of Systemic Lupus Erythematosus Sera with Cellular and Virus Antigen Preparations <i>Theodore Pincus, Alfred D. Steinberg, Neil R. Blacklow and John L. Decker</i>	873
Search for Type-C Oncornavirus-Related Genetic Information in Tissues from Patients with Systemic Lupus Erythematosus <i>Gurmit S. Aulakh, John T. Hicks, W. John Martin and Paul E. Phillips</i>	880
HLA-C Locus Antigens in HLA-B27 Associated Arthritis <i>Frank C. Arnett, Marc C. Hochberg and Wilma B. Bias</i>	885
High Prevalence of HLA-Cw1 and Cw2 Antigens in Spondylarthritis <i>Franklin Kozin, Rene Duquesnoy, Glenn E. Rodey, Robert W. Lightfoot, Jr. and Lawrence M. Ryan</i>	889
Mechanisms of Cellular Interaction with Monosodium Urate Crystals: IgG-Dependent and IgG-Independent Platelet Stimulation by Urate Crystals <i>Mark H. Ginsberg and Frank Kozin</i>	896
Humoral Immune Stimulation and Antiepithelial Antibodies in Yersina Infection <i>Marianne Gripenberg, Aaro Miettinen, Pekka Kurki and Evert Linder</i>	904
Involvement of Prostaglandins from Rheumatoid Synovium in Inhibition of Articular Cartilage Metabolism <i>L. Lippiello, K. Yamamoto, D. Robinson and H. J. Mankin</i>	909
Fate of Antigen after Intravenous and Intraarticular Injection into Rabbits <i>Hal Mitnick, Sylvia Hoffstein and Gerald Weissman</i>	918
Complement-Fixing Hidden Rheumatoid Factor in Children with Benign Rheumatoid Nodules <i>Terry L. Moore, Robert W. Dorner and Jack Zuckner</i>	930
Complement-Fixing Hidden Rheumatoid Factor in Juvenile Rheumatoid Arthritis <i>Terry L. Moore, Jack Zuckner, Andrew R. Baldassare, Terry D. Weiss and Robert W. Dorner</i>	935
Effects of Diphosphonates on Glycosaminoglycan Synthesis and Proteoglycan Aggregation in Normal Adult Articular Cartilage <i>Marshall Palmoski and Kenneth Brandt</i>	942
Reevaluation of the Ammonium Sulfate Assay for DNA Antibody <i>Robert L. Rubin, Joyce Lafferty and Ronald I. Carr</i>	950

Familial Deficiency of Two Subunits of the First Component of Complement: Clr and Cls Associated with a Lupus Erythematosus-Like Disease	
<i>Stanley L. Lee, Stanley L. Wallace, Richard Barone, Livia Blum and P. Harvey Chase</i>	958
Acute Hematogenous Osteomyelitis Progressing to Septic Synovitis and Eventual Pyarthrosis: The Vascular Pathway	
<i>Steven G. Atcheson and John R. Ward</i>	968
Case Report: Constrictive Pericarditis in Systemic Lupus Erythematosus: Demonstration of Immunoglobulins in the Pericardium	
<i>Edwin J. Jacobson and Michael J. Reza</i>	972
Case Report: Legionnaires' Disease in a Patient with Systemic Lupus Erythematosus	
<i>Ralph F. Jacox and I. Donald Stuard</i>	975
Case Report: Echovirus-Associated Polyarthritis: Report of a Case with Synovial Fluid and Synovial Histologic Characterization	
<i>J. Wolfe Blotzer and Allen R. Myers</i>	978
Case Report: Transverse Myelitis in Mixed Connective Tissue Disease	
<i>Terry D. Weiss, James S. Nelson, Robert M. Woolsey, Jack Zuckner and Andrew R. Baldassare</i>	983
Government Affairs: The Future of Federal Support for Health Research	
<i>Roland W. Moskowitz</i>	987
In Memoriam: Dr. Jacques Forestier	
<i>Milovan Rakic</i>	989
Letters.....	991
ARA Announcements.....	1000
Annual Indexes	1001

VOL. 21

NOVEMBER-DECEMBER

No. 8 SUPPLEMENT

Twenty-Third Rheumatism Review..... R1-R312

INDEXES

AUTHOR INDEX

Page numbers in italics refer to abstracts. Authors published in the June supplement are indexed in that volume.

A

- Abel T, 539
- Abeles M, 58
- Abrass CK, 539
- Adams LE, 565
- Adelstein E, 604
- Agnello V, 540
- Ahmed T, 221
- Alarcón-Segovia D, 295, 493, 866
- Albers JW, 723
- Alekberova AS, 23
- Ally AI, 492
- Aldo-Benson M, 605
- Alspaugh MA, 540, 590
- Altman RD, 541, 576
- Ambanelli U, 396
- Anastassiades TP, 461
- Anderson K, 249, 582
- Andreis M, 310
- Andres C, 603
- Antonovych T, 204
- Appelboon T, 174
- Arbette AE, 540
- Arend WP, 504
- Arinovic R, 742
- Arnett FC, 542, 885
- Arnold W, 603
- Arroyave CM, 542
- Arthur RE, 579
- Atcheson SE, 968
- Athreya BH, 429
- Aulakh GS, 880
- Austin TW, 574
- Avioli LV, 367
- Ayers RC, 557

B

- Bacon PA, 560
- Bailey AJ, 545
- Baldassare AR, 579, 935, 983
- Baker MA, 585
- Ball GV, 870
- Ballou SP, 543
- Balow JE, 580
- Balow JL, 570
- Banner BF, 780
- Barada FA, 543
- Baraf HSB, 544
- Baratz M, 604
- Barnett EV, 574
- Barone R, 958
- Barth WF, 271
- Bartholomew FN, 544
- Bartholomew LE, 544, 588
- Batey ME, 690
- Batson JW, 229
- Baum J, 229, 699
- Bear RA, 554

- Beighton P, 545
- Bell DA, 183, 545, 574
- Benderly A, 391
- Bennett JC, 152, 531, 557
- Bennett M, 603
- Bennett PH, 467
- Bennett RM, 546
- Bensen WG, 844
- Bentley G, 669
- Berg E, 396
- Berney S, 863
- Bernhard GC, 587
- Bernstein BH, 401, 593
- Bias WB, 542, 885
- Biegel A, 605
- Bishko F, 868
- Biundo JJ Jr, 590
- Black CM, 545
- Blacklow NR, 873
- Blanford AT, 723
- Blotzer JW, 978
- Bluestein HG, 177, 546
- Bluestone R, 175, 285, 774
- Blum L, 862, 958
- Boerbooms AMTH, 348
- Bohan A, 62
- Bole GG, 599
- Bong DA, 546
- Border WA, 539
- Bordwell B, 602
- Botzenhardt U, 547
- Bowden RE, 570
- Boyd R, 559
- Boyer RS, 547, 582
- Brandt KD, 7, 453, 575, 583, 942
- Braun AI, 221
- Braun WE, 528, 569
- Braunstein EM, 161
- Bresnihan B, 560
- Breth G, 995
- Brickness KD, 774
- Brighton CT, 566, 585
- Brinkerhoff CE, 547, 745
- Briney WG, 839
- Broder I, 280
 - vok I, 774
 - wn BW Jr, 576
 - wn DH, 441
- E own HLG, 675
- Brown MD, 541
- Brumfield H, 549
- Brunner CM, 289
- Buchert P, 596
- Buchnall R, 560
- Bunch TW, 548
- Burkholder S, 196
- Burnstein SL, 260
- Burrington M, 407
- Busscher H, 174
- Buyss WCM, 348
- Bywaters EGL, 388, 739

C

- Calabro JJ, 167, 260
- Caldwell DS, 544
- Calin A, 548
- Campion DS, 62, 834, 994
- Carboni JM, 564
- Cardella CJ, 554
- Carlo JR, 549
- Carpenter JC, 549
- Carr ME, 562
- Carr RI, 587, 950
- Carroll MG, 731
- Carson DA, 438, 550, 593, 820
- Cassidy JT, 554
- Castor CW, 550
- Cathcart ES, 153, 592, 603
- Catherole L, 545
- Chandler RW, 575
- Chang Y, 170
- Chase PH, 958
- Cheung HS, 551
- Chia D, 574
- Chodirkar WB, 585
- Chow D, 598
- Christian CL, 264, 343
- Chused TM, 551, 580
- Classen JN, 606
- Clayman MD, 383
- Cleland LG, 183
- Clements PJ, 62, 557, 994
- Cline MJ, 560
- Clough JD, 391
- Cohen AS, 153
- Cohen PL, 551
- Cook EH, 608
- Cooke CR, 600
- Cooke TDV, 81, 516, 556
- Combs JJ, 548
- Cooney FD, 271
- Cottney J, 441
- Cottrell WH, 551
- Craig C, 196
- Crissman JD, 596
- Crockson AP, 491
- Crockson RA, 491
- Crowe W, 391
- Cummings NA, 596
- Cunnane SC, 492
- Curd J, 1, 177
- Curtis DL, 827

D

- Damergis J, 271
- D'Angelo WA, 576
- Daniels TE, 337, 584
- Davis JS, 17
- Davis P, 234, 407, 552
- Davis WH, 754
- Dayer JM, 552

- Decker JL, 570, 586, 594, 665, 798, 873
- DeHeer DH, 567
- DeHoratius RJ, 553, 561
- de la Kasep GI, 540
- De La Fuente JR, 493
- Delahaye RP, 993
- Dell'Italia LJ, 167
- Denko CW, 496
- Diamond HS, 37, 553
- Diaz-Jouanen E, 295, 493
- Dimant J, 393
- Disney TF, 574
- Dito WR, 224
- Djaldetti M, 608
- Dorner RW, 579, 930, 935
- Dorwart BB, 513
- Douglas SD, 601
- Doury P, 993
- Dunne JV, 767
- DuPont B, 558
- Duquesnoy R, 889
- Duvic M, 414
- Dyck RF, 554

E

- Edwards NL, 554
- Ege GN, 585
- Ellman MH, 613
- Ely PH, 599
- Emery H, 599
- Emlen W, 555
- Engel AG, 548
- Engleman E, 690
- Enriquez RD, 148, 578
- Epstein WV, 827
- Espinosa LR, 72
- Evans JA, 555
- Exaire E, 578

F

- Falbo A, 588
- Fam AG, 844
- Famaey JP, 174
- Farber N, 599
- Farmer PM, 393
- Farrar JJ, 571
- Faure G, 997
- Feigenbaum SL, 575, 577
- Ferguson L, 613
- Ferraccioli GF, 396
- Filipowicz-Sosnowska AM, 699
- Filo R, 575
- Finegold SM, 774
- Fisher WD, 556
- Fleischmajer R, 418
- Fleischmann RM, 811
- Foad BS, 565
- Folomeeva O, 23

- Ford DK, 330
 Fotino M, 558
 Fox IH, 554, 603
 Fox R, 548
 Frank MM, 563, 580
 Frayha RA, 611, 741
 Friedman DM, 556
 Fries JF, 576, 600, 601
 Fritzler MJ, 556, 591
 Furr P, 792
 Fursi DE, 62, 557
 Fuson EW, 557
 Fuzesi L, 600
 Eye KH, 337, 584
- G**
- Gagliardi S, 868
 Gale R, 557
 Gall EP, 224, 513
 Gallagher JD, 798
 Ganuza C, 605
 Garcia-Morteo O, 868
 Gargano FP, 541
 Gaucher A, 997
 Gay S, 418
 Gelfand E, 603
 Gerber RC, 548
 Getzy L, 586
 Gewurz A, 28
 Gewurz H, 28
 Gibofsky A, 558
 Gibson DJ, 548
 Gilliam JN, 566
 Gilliland BC, 330, 581
 Gillings DB, 210
 Ginsberg MH, 558, 896, 995
 Ginzler E, 37
 Gladman DD, 559
 Glasscock RJ, 539
 Godfrey SM, 17
 Godzeski CW, 559
 Gofton JP, 869
 Goldberg LS, 560
 Goldberg VM, 560, 579, 586
 Golden HE, 780
 Goldman JA, 72
 Goldstein IM, 583
 Good A, 597
 Goodwin JS, 561
 Gordon DA, 280, 554, 585
 Gorog P, 256
 Gottlieb NL, 92, 282, 704
 Graham J, 76
 Granberry WM, 561
 Granier LS, 780
 Granier R, 993
 Gratwick GM, 343
 Gray RG, 92, 494
 Graze P, 557
 Green I, 657
 Griffiths MM, 97
 Gripenberg M, 904
 Gruskin BJ, 168
 Guggenheim SJ, 595
 Gunther SF, 271
 Guobys H, 120
 Guzman L, 742
- H**
- Hadler NM, 210, 562
 Hahn, B, 196
 Hakansson L, 107
 Halla JT, 497, 562, 645
 Hallgren R, 107
 Halushka PV, 571
 Halverson PB, 563
 Hamburger MI, 563
 Hammerman D, 559
 Hansen JA, 558
 Hanson V, 401, 573, 593
 Hardin JA, 564
 Hardin JG, 497, 562, 645, 871
 Harris ED, Jr, 137, 362, 547, 591, 745
 Harris R, 62
 Harth M, 574
 Hashimoto EG, 581
 Hasselbacher P, 353, 565, 740
 Hastings DE, 555
 Hazard GW, 167
 Healey LA, 565
 Henderson ES, 260
 Henke CJ, 827
 Henoch MJ, 229
 Herman JH, 596
 Hess EV, 397, 565
 Hicks JT, 880
 Himenstein M, 283
 Ho PPK, 133
 Hochberg MC, 542, 885
 Hoffstein S, 918
 Hoffstein S, 594
 Holbrook T, 593
 Holden D, 553
 Holmes EW, 544
 Hoover PL, 592
 Hopper J, 598
 Horn JR, 709
 Horrobin DF, 492
 Horton JE, 571
 Horwitz DA, 543
 Houle PA, 761
 Howell DS, 579, 588, 597
 Hübscher O, 868
 Huckman MS, 780
 Hughes GRV, 560, 597
 Hunder GG, 145, 175
 Hungerford DS, 606
 Hurd ER, 310, 566
 Huston KA, 145
 Hymowitz R, 731
- I**
- Ilfeld D, 204
 Ilstrup DM, 548
 Imbus HR, 210
 Inman R, 582, 849
 Irwin D, 461
 Isaacson AS, 401
 Israel H, 561
- J**
- Jackson EA, 992
 Jacobelli S, 447
- Jacobs JC, 129
 Jacobson EJ, 972
 Jacox RF, 975
 Jacquot JM, 996
 Jasim HE, 598
 Jee WS, 581
 Jensen F, 593
 Jimenez FJ, 148
 Jimenez J, 578
 Jimenez SA, 566
 Joachim C, 600
 John JT, 192
 Johnson AH, 580, 586
 Johnson M, 554
 Jones JV, 567
 Jones M, 596
 Jones T, 597
 Jordan E, 260
 Jowsey JO, 715
 Jubran F, 611
 Jusenaita J, 20
- K**
- Kagen LJ, 568
 Kahaleh MB, 567
 Kaklamani P, 279
 Kamel H, 441
 Kaminska J, 603
 Kang AH, 584
 Kano K, 634, 639
 Kaplan D, 37
 Kaplan F, 566
 Kaplan PE, 993
 Kaplan RA, 567
 Kaplan SB, 575, 577
 Kapur JJ, 709
 Kapusta MA, 568
 Karmali RA, 492
 Karmazyn M, 492
 Karthikeyan G, 862
 Kaslow RA, 473, 480
 Kassan SS, 568
 Katz A, 554, 585
 Kay DR, 599
 Keane SP, 723
 Keiser JR, 570
 Kettlun AM, 447
 Keystone EC, 539, 559, 569, 792
 Khan MA, 528, 569
 Kiem IM, 92
 Kilduff FJ, 167
 Kimberly RP, 570
 King KK, 401
 King R, 549
 King SR, 550
 Kirk KA, 564
 Klassen LW, 204, 414
 Kleerekoper M, 367
 Klein J, 547
 Klein R, 343
 Klippen JH, 546, 570, 586, 594
 Knotts L, 196
 Koehler BE, 280
 Koffler D, 289
 Kohmoto K, 803
 Kojer M, 243
 Kolarz G, 243
- L**
- Lafferty J, 950
 Lamont EW, 557
 Landing B, 593
 Lanza FL, 572
 Laskin CA, 844
 Lawley TJ, 580
 Lawley TL, 563
 Lawrence S, 438, 550
 Layfer LF, 567, 572, 780
 Lee MY, 504
 Lee SL, 754, 958
 Leeb J, 785
 Leers SA, 167
 Lehman TJA, 573
 Leibfarth JK, 316
 Lentle BC, 234
 LeRoy EC, 567, 571, 576
 Lessell S, 1
 Levine PH, 137
 Levitin PM, 210
 Levy J, 62, 391
 Lewis AJ, 441
 Ley J, 461
 Lian JB, 573
 Liang G, 587
 Liebling MR, 574
 Lightfoot RW, 889
 Ligler FS, 551
 Linder E, 904
 Linn JE, 645
 Lint TF, 28
 Lippiello L, 909
 Lipton M, 583
 Little HA, 844
 Litwin A, 565
 Liu YK, 731
 Liyanage IS, 998
 Liyanage SP, 998
 Llorente L, 493
 Lockshin M, 600
 Logie JM, 565
 Lorber A, 785
 Losalluto J, 310
 Louie JS, 51, 539, 547, 582, 834
 Lourdes JM, 148
 Lowenstein MB, 58, 992
 Lowther DA, 675

Lubeck MJ, 839
Lyons H, 556

M

MacFarlane J, 575
Machtey I, 283
Mackenzie AH, 576
Madura J, 605
Magilavy DB, 554
Mainardi CL, 137
Major JC, 704
Makarova O, 45
Makuc D, 210
Malawista SE, 564, 735
Mandel N, 613
Mandell B, 594
Mankin HJ, 761, 909
Manku MS, 492
Mann DL, 580, 586
Mannik N, 330, 555, 581
Maricq HR, 173, 576
Markenson JA, 266, 600
Martel W, 161, 739
Martin WJ, 880
Masi AT, 473, 480, 575, 576, 577
Massias P, 996
Matsuta K, 588
Matusi AA, 120
McCain GA, 574
McCarty DJ, 563, 723
McConkey B, 491
McCombs C, 578
McCord WC, 834
McDevitt HO, 690
McDuffie FC, 549
McGee JA, 575
McKinley P, 595
McLaughlin GE, 599
McLeod B, 567
McLeod RL, 306
McShane DJ, 576
Meachim G, 669
Mecker T, 562
Medger TA, 576
Meenan RF, 827
Mehta J, 196, 594
Meigel WN, 418
Meisel AD, 553
Mellors JW, 577
Mellors RC, 577
Mendes NF, 326
Menzel J, 243
Mergenhagen, SE, 571
Messner RP, 561
Metges PJ, 993
Michalski JP, 306, 337, 578, 584
Miettinen A, 904
Milgrom F, 634, 639
Miller C, 196
Miller ML, 681
Mintz G, 148, 578
Mitnick H, 918
Miyawaki S, 803

Moeschberger M, 596
Mond JJ, 551
Monteil MM, 652
Moore MF, 556
Moore TL, 114, 579, 767, 820, 930, 935
Morgan AR, 407, 552
Morgan GJ, 362
Morgan RO, 492
Morris AD, 596
Moskovitz N, 210
Moskowitz RW, 166, 560, 579, 586, 987
Moss S, 597
Moutsopoulos HM, 551, 580, 798
M'Seffar A, 585
Mueller MN, 581
Müller-Eberhard HJ, 177, 567
Muniz O, 579, 597
Murphy WA, 367
Murray GC, 652
Musatti C, 326
Myers AR, 589, 978

N

Nahir M, 391
Namey TC, 399
Nardella FA, 581
Nassonova VA, 23
Nelson AM, 145, 715
Nelson RS, 572
Nelson JS, 983
Netter P, 997
Nies KM, 51, 539, 547, 582, 834
Nimni ME, 551
Nishimaki T, 634, 639
Norman CS, 539
Norman DA, 811
Noronha A, 598

O

O'Brien WM, 398
Ofuji T, 803
Oh JH, 72
Ohno O, 81, 516
Opelz G, 337
Osterland CK, 72
Ottaway JM, 441
Oxenhander RW, 593

P

Pachman L, 604
Paget SA, 249, 558, 582
Palmoski M, 583, 942
Panush RS, 172
Parciany RK, 572
Partamian L, 611
Passas C, 168
Patarroyo M, 558
Pattin S, 993
Paty JG Jr, 171, 284
Patzakis MJ, 401
Paulus HE, 62
Paxon CS, 592
Pearson CM, 170, 604

Pek S, 550
Pepper BJ, 97
Perez HD, 583
Perlisch JS, 418
Perlman SG, 271
Perricone E, 453
Persellin RH, 316, 652
Pesce M, 129
Peter A, 785
Peters CJ, 767
Peters RS, 573
Petty DA, 587
Phillips PE, 249, 266, 582, 584, 880
Pigg JS, 286
Pinals RS, 285, 727
Pinching AJ, 597
Pincus T, 553, 873
Pisko E, 595
Pita JC, 579
Pittsley RA, 584
Plotz PH, 563, 570
Poole AR, 556
Pope C, 569, 792
Postlethwaite AE, 584
Pourer J, 997
Price TH, 504
Pritchard KI, 554, 585
Pruzanski W, 171

R

Raffoux C, 997
Rakic M, 397, 989
Ralph ED, 574
Ramcharan S, 690
Reeves JP, 204
Reginato AJ, 585
Reinecke RD, 588
Reinertsen JL, 204, 383, 586
Resnick D, 1, 395, 999
Reynolds MD, 377
Reynolds P, 544
Reza M, 604, 774, 972
Rich K, 603
Richards AJ, 280, 865
Riggs BL, 715
Rightsel WA, 575
Rimon D, 283
Riskin W, 282
Rivero SJ, 295, 493
Robbins DL, 114, 820
Roberts JL, 28
Roberts N, 557
Robertson JS, 595
Robinson D, 909
Robinson MF, 567
Robles E, 578
Robles-Saavedra EJ, 148
Roder JC, 545
Rodey GE, 889
Rodnan GP, 576
Rogoff JB, 865
Rose JE, 114
Rosenthal CJ, 699
Rosner IA, 586
Ross GL, 281
Rothfield N, 602
Roubinian J, 589

Royer GL, 572
Rzotropowicz-Denisiewicz K, 699
Rubin RL, 587, 950
Ruddy S, 549
Russell AS, 407, 552
Ryan LM, 587, 889
Rynes RI, 588

S

Sakane T, 657
Samuelson CO, 681
Sandy JD, 675
Sanford KG, 863
Santer VB, 675
Santoli D, 553
Santos L, 326
Sapag-Hagar M, 447
Sapolsky AI, 588
Saurino BC, 183
Sauter S, 549
Sawada S, 589
Sawaya J, 611
Saxon A, 582
Scarola JA, 589
Schaller JG, 599
Scharf J, 391
Schechter SL, 864
Scheinberg MA, 326
Schimmer BM, 589, 740
Schlesinger M, 37
Schlumpf U, 280
Schrohenloher RE, 562
Schumacher HR, 353, 429, 513, 585, 590, 597
Schwabe AD, 573
Scopelitis E, 590
Scott JT, 742
Scott ME, 550
Segond P, 996
Seleznick M, 37
Sargent JS, 192, 343
Seyer JM, 584
Shainhouse Z, 554
Shapiro RF, 1, 599
Sharp, GC, 576, 593, 604
Sharp, JT, 169
Sharro SO, 551
Shepard JD, 591
Sheps S, 549
Siegel RC, 591
Silverman M, 554, 592, 595, 839
Silverman SL, 592
Simkin PA, 592
Simon T, 785
Singhal SK, 545
Singsen BH, 401, 593
Skilton JC, 864
Skinner M, 153
Skosey JL, 598, 995
Slaughter L, 593
Slusser D, 210
Smith CA, 559
Smith CB, 97
Smith WE, 441
Smolen J, 243

- Smythe HA, 539
 Snyder SM, 306
 Sobol N, 393
 Sokoloff L, 754
 Solomon SD, 279
 Southard GL, 133
 Spagnola AM, 467, 564
 Spieler PN, 564
 Spilberg I, 594
 Spitz JR, 540
 Sponzilli EE, 690
 Stahl NI, 594, 665
 Stankaitiene DJ, 120
 Starkebaum G, 504
 Steere AC, 564
 Steffen C, 243
 Steigerwald JC, 592, 595
 Steinberg AD, 204, 414, 570,
 586, 657, 798, 873
 Stevens MB, 589, 606
 Stevens R, 582
 Stockman A, 742
 Streiff F, 997
 Struth AG, 595
 Stuard ID, 975
 Sturgeon JFG, 585
 Sullins D, 596
 Sun NC, 547
 Sundsmo JS, 177
- T**
- Tabatabai MR, 596
 Talal N, 23, 306, 337, 578, 584,
 589, 853
- Tan EM, 542, 556
 Taplits MS, 596
 Tateishi H, 81
 Taylor G, 792
 Taylor-Robinson D, 569, 792
 Teitelbaum SL, 367
 Templin DW, 224
 Tenenbaum J, 554, 597
 Teresaki PI, 337, 467
 Thomson ABR, 234
 Travers RL, 597
 Trenholm GM, 572
 Turner R, 595
- U**
- Uberoi S, 598
 Ugai K, 598
 Urman JD, 58
 Urowitz MB, 539, 559
 Utsinger PD, 210, 599
- V**
- Valentine TV, 599
 van der Rest M, 556
 van de Sande JH, 591
 Vansant J, 192
 Vasey FB, 72
 Vater CA, 591
 Vaughan JH, 114, 567, 593,
 767, 820
 Vazquez T, 613
 Venge P, 107
 Verity MA, 547
 Vigliani G, 761
- Vignos PJ Jr, 391
 Vitetta ES, 551
 Volanakis JE, 562
- W**
- Walker SE, 599, 709
 Wallace C, 599
 Wallace SL, 862, 958
 Warburg M, 600
 Ward JR, 681, 968
 Wasner C, 600, 601
 Watson JI, 591
 Waytz PM, 601
 Wedgwood R, 599
 Weinberger A, 740
 Weiner M, 37
 Weinstein A, 58, 168, 585, 602
 Weiss TD, 579, 935
 Weissman G, 278, 918
 Werb Z, 137
 White BS, 539
 Whitten ED, 557
 Whyte MP, 367
 Wiesner KB, 1, 599
 Wilcox S, 785
 Wiletzki C, 694
 Wilkinson R, 72
 Willans M, 183
 Williams GW, 204
 Williams RC Jr, 23
 Wilske KR, 565
 Wilson CH Jr, 617
 Wilson WF, 592
 Winchester RJ, 558
- Winfield JB, 17, 289
 Witorsch P, 271
 Woessner JF, 588
 Wohlgethan JR, 603
 Wolf RE, 238
 Wolfe F, 576
 Wolfe JF, 593, 604
 Wood A, 461
 Woolsey RL, 192
 Woolsey RM, 983
 Worthington JW, 548
 Wortmann RL, 603
 Wright V, 619
- Y**
- Yamamoto K, 909
 Yaron I, 604, 694
 Yaron M, 604, 608, 694
 Yatts P, 595
 Yelin EH, 827
 Yeni P, 996
 Young AL, 133
 Young-Rodenck M, 568
 Yount WJ, 210, 549
 Yunus M, 167
- Z**
- Zapanta M, 605
 Zein N, 605
 Zeitz H, 28
 Ziff M, 310, 547, 551, 598
 Zizic TM, 589, 606
 Zor U, 604, 694
 Zuckner J, 579, 930, 935, 983
 Zurier RB, 571
 Zvaifler NJ, 546

SUBJECT INDEX

Arthritis and Rheumatism, Volume 21, Numbers 1 through 8, 1978

Page numbers in italics refer to papers presented at the 42nd Annual Scientific Session of the American Rheumatism Association, May 31-June 2, 1978. The Proceedings of the Conference on New Directions for Research in Systemic Lupus Erythematosus and The Twenty-Third Rheumatism Review are indexed separately.

A

- ACC, *see* Articular chondrocalcinosis
Acetylation phenotypes
 distribution of in systemic lupus erythematosus, 192-195
 renal disease and, 194
Acromegaly, carpal tunnel syndrome and, 221
ACT, *see* Articular collagenous tissues
Active urinary sediment, effect on infection in systemic lupus erythematosus, 42
Acute hematogenous osteomyelitis, septic synovitis and, 968-971
 in adults, 968
 in children, 968
 pyarthrosis and, 968-971
Acute rheumatic fever, *see* Rheumatic fever, acute
ADCC, *see* Antibody-dependent cell-mediated cytotoxicity
Adjuvant arthritis
 aspirin as treatment for, 256
 platelet aggregates in, 256-259
 in rats, 169-170, 256-259
 thrombocytosis and, 256-259
 virazole effect on, 568
Agammaglobulinemia, immunodeficiency in, 554
Ammonium sulfate assay, reevaluation of, 950-957
Amyloid arthritis, multiple myeloma and, 148
Amyloid arthropathy
 chondrocalcinosis and, 587-588
 dysproteinemia and, 587-588
Amyloidosis
 carpal tunnel syndrome and, 221, 223
 chemical nature of, 153-156
 genesis of, 156-158
 investigation of, current trends, 153-160
 in juvenile rheumatoid arthritis, 699-703, 867-868
 pathogenetic pathways in development of, 158
ANA, *see* Antinuclear antibodies
Ankylosing vertebral hyperostosis, *see* Forestier's disease
Ankylosing spondylitis
 in American blacks, 528-530
 buttressing of femoral neck in, 161-162
 in children, 401-406
 diagnostic criteria of, 383
 HLA antigens and
 HLA-B7 and, 528-530
 HLA-B27 and, 337, 383, 528-530, 885
 HLA-C locus antigens in, 886
 HLA-DRw and, 997
 rheumatoid arthritis and, 383-389
 rheumatoid vasculitis and, 383-389
 Sjögren's syndrome and, 383-389
 spinal pseudoarthrosis in, 485-490
 subgroup of, 528-530
 total hip replacement in, 401-406
Anti-DNA antibodies
 ammonium sulfate assay for, 950-957
 central nervous disease and, 289-294
 detection of, 390-391
 immunochemical characteristics of, 543
 peripheral blood lymphocyte synthesis of, 582
 in systemic lupus erythematosus, 289-294, 543, 582, 602, 950
 spontaneous responses in autoimmune mice, 545
Anti-DNA complexes, in systemic lupus erythematosus, 17-22, 24-25
Anti-antibody inhibition test, 639, 641, 642
Antibody-dependent cell-mediated cytotoxicity
 assay reproducibility of, 100
 rheumatoid synovial cells susceptibility to, 97-105
 time course of, 101
Antiepithelial antibodies, in Yersinia infection, 904-908
Antigen
 fate of after injection in rabbits, 918-929
 HLA, *see* HLA antigens
Antiummunoglobulins
 in osteoarthritis, 120-128
 properties of, 120-128
 in rheumatoid arthritis, 120-128
 reactive with human and rabbit IgG, 120-128
 in rheumatic fever, 120-128
Antilymphocyte antibodies
 central nervous system disease and, 289-294
 in systemic lupus erythematosus, 23-27, 289-294
Antinuclear antibodies (ANA)
 in rheumatoid arthritis, 645-651
 rheumatoid factor and, 645-651
Antipolynucleotide antibodies, in systemic lupus erythematosus, 23-27
Antiviral antibodies, in systemic lupus erythematosus, 23-27
ARA Preliminary Criteria for classification of systemic lupus erythematosus, suggested revision of, 602
Arteritis
 declassification of, 171
 giant cell, 365, 391-393
 non-giant cell temporal, 362-366
 temporal, 362-366
Arthritis, *see also* Rheumatic diseases, Rheumatoid arthritis
 adjuvant, *see* Adjuvant arthritis
 amyloid, 148
 antigen-induced, 675-680
 axial psoriatic, 74
 cartilage matrix components, effects on, 677-678
 in children, 401-406
 Danazol and, 493-494
 ferritin-induced, 81-91
 gonococcal, *see* Gonococcal arthritis
 hemophilic, *see* Hemophilia
 HLA-B27 and, 542, 995-998
 HLA-C and, 542, 885-888
 infectious agent associations with, 575
 inherited deficiency of fifth component in, 792-797

as intestinal bypass postsurgical complication, 599, 605
juvenile rheumatoid, *see* Juvenile rheumatoid arthritis
lyme, *see* Lyme arthritis
mycoplasma pulmonis induced, 792–797
myeloma, 148
peripheral psoriatic, 72–76
proteoglycan, effects on, 675–680
psoriatic, *see* Psoriatic arthritis
rheumatoid, *see* Rheumatoid arthritis
satellite clinic, 727–730
septic, 150
severity, numerical measure of, 348–352
sulfanilamidoindazole, 681–689
Tc-pertechnetate uptake in, 348–352
traumatic, 76–80
zinc and penicillamine therapy combined in, 492
Arthritis-dermatitis syndrome, as intestinal bypass postsurgical complication, 599
Arthropathy
congenital flexion contractures of fingers in, 429–437
cutaneous polyarteritis and, 281–282
familial, 429–437
idiopathic Charcot, *see* Idiopathic charcot arthropathy
inflammatory and noninflammatory, 461–466
juvenile rheumatoid arthritis contrasted to, 433
pathologic features of, 429–437
synovial cell growth in, 461–466
Articular cartilage
collagenase activity, 761–766
horizontal splitting in patellar, 669–674
in inflammatory arthritis, 909
osteoarthritis and, 761–766
prostaglandins and, 909–917
proteoglycan content and synthesis in, 675–680
rheumatoid arthritis and, 909
Articular chondrocalcinosis, 447–452
Articular collagenous tissues
changes in, 83–86
in ferritin-induced arthritis, 81–91
immunoglobulin aggregates interactions with, 516–527
immunologically induced changes in, 86
Aseptic necrosis, thalassemia and, 280
Aspirin, *see also* Salicylates
for adjuvant arthritis, 256
for migrainous phenomena, 14
Atypical axial osteomalacia, 715–722
ankylosing spondylitis and, 715–722
treatment for, 722
vitamin D and, 715, 722
Autoimmune anemia, mixed connective tissue disease and, 995–997
Autoimmune neutropenia, *see* Neutropenia
Autoimmunity, 853–862
autoimmune disease and, 856–858
Nafoxidine effect on, 414–417
self-recognition and, 854–856
sex hormones and, 414–417
Azathioprine
and polymyositis, 548
and rheumatoid arthritis, 539
and systemic lupus erythematosus, 39–40, 570

B

Back pain, transaxial tomography in assessment of, 541–542
Behcet's syndrome, clinical associations with, 623–624, 626

Benign rheumatoid nodules (BRN), rheumatoid factor in children with, 930–934
Betamethasone for flexor tenosynovitis, 94
Bone marrow transplantation, skin changes following, 557
Bony ankylosis, rheumatoid arthritis diffuse idiopathic skeletal hyperostosis and, 4
Bony sclerosis, rheumatoid arthritis diffuse idiopathic skeletal hyperostosis and, 4
BRN, *see* Benign rheumatoid nodules
Bursitis
hemochromatosis and, 844–848
rheumatoid arthritis secondary to, 147–149
subacromial, 147–149
Buttressing of femoral neck, 161–164
in ankylosing spondylitis, 161–162
cause of, 161–162
diagnostic value of, 161–164
in ischemic necrosis, 161–162
in osteoarthritis, 161–163
in rheumatoid arthritis, 161–163

C

C-reactive protein
in rheumatoid arthritis, 491
in systemic lupus erythematosus, 605
C2 deficiency (C2D)
antinuclear antibodies in, 28
complement activity in serum in, 30
dermatitis in, 28
family studies in, 30
with fulminant lupus erythematosus, 28–36
joint involvement in, 28
nephritis and, 28–35
photosensitivity in, 28
protein levels and, 31
renal involvement in, 28
in systemic lupus erythematosus, 28–35
C2D, *see* C2 deficiency
C3 serum, level in systemic lupus erythematosus, 602
C4, metabolism in rheumatoid arthritis, 567–568
Calcium ionophore, lymphocyte response to, 326–329
rheumatoid arthritis and, 326–329
systemic lupus erythematosus and, 326–329
Calcium pyrophosphate dihydrate crystals, 447–452
Capillary microscopy for clinicians, 173
Carboxyglutamate, vitamin K dependent synthesis of, 573–574
Carpal and tarsal multicentric osteolysis, *see* Idiopathic multicentric osteolysis
Carpal tunnel syndrome
acromegaly and, 221
age distribution of patients with, 223
amyloidosis and, 221, 223
cause of, 223
Danazol and, 493–494
definition of, 221
diabetes and, 221
electrical studies in, 865
gout and, 221
myxedema and, 221, 223
polymyalgia rheumatica and, 221–223, 865
rheumatoid arthritis and, 221–223
sex distribution of patients with, 223
steroid therapy in, 223
tenosynovitis as cause of, 223
Cell-mediated cytotoxicity, in rheumatoid arthritis, 601–602
Central nervous system disease

anti-DNA antibodies in, 289–294
anti-Sm in, 293
antilymphocyte antibodies in, 289–294
serologic studies in, 289–294
serum hemolytic complement activity in, 289
systemic lupus erythematosus and, 289–294
Central retinal vein occlusion, in systemic lupus erythematosus, 839–843
Cervical disc disease, origin of in rheumatoid arthritis, 737–739
Chondrocalcinosis
 amyloid arthropathy and, 587–588
 articular, 447–452
 cartilage phosphatases in, 597
 as cause of arthritis, 174
Chrysotherapy, *see also* Gold compounds
 in cryoglobulinemia, 790
 efficacy of, 513–515
 in extrinsic bronchial asthma, 790
 immunoglobulin synthesis and, 785–791
 immunosuppressive effect of, 785
 in macroglobulinemia, 790
 nitritoid reaction in, 868–869
 ocular chrysiasis after, 704–708
 ophthalmologic complications of, 704–708
 in pemphigus, 790
 postinjection site pain syndrome in, 868–869
 in psoriatic arthritis, 513–515
 in rheumatoid arthritis, 513–515, 785–791
 rheumatoid factor and, 785–791
 in Sjögren's syndrome, 790
 toxicity of, 513–515
CIC, *see* Immune complexes
Circulating immune complexes, *see* Immune complexes
C1q-sepharose eluates, characterization of, 20
CNS disease, *see* Central nervous system disease
Colchicine, 731–736
 excess dosage effects, 733, 735–736
 gout, as treatment for, 731, 736
 marrow aplasia induced by, 731–736
Collagen
 biosynthesis during repair of articular cartilage, 551
 production of by multinucleated cell cultures, 745–753
Complement components, *see also* C2 deficiency, C3 serum, C4
 familial deficiency of subunits of first, 958–967
 fifth, inherited deficiency of in arthritis, 792–797
Complement pathways
 alternative in nephritis, 28–35
 properdin, 30–32
CON-A, *see* Concanavalin-A
Concanavalin-A (CON A)
 levamisole and, 326–329
 lymphocyte response to, 326–329
 rheumatoid arthritis and, 326–329
 systemic lupus erythematosus and, 326–329
Connective tissue disease, *see also* Mixed connective tissue disease
 nuclear antigens and, 803–810
Corticosteroids
 antiphlogistic effect in paraarticular disorders, 94
 bacterial infections, relation to, 112
 for giant cell arteritis, 365
 intratendon sheath, 92–96
 in osteoarthritis, 556
 in polyarthritis, 365
 in rheumatoid arthritis, 92, 96, 110–112
 associated with tenosynovitis, 92–96
 in systemic lupus erythematosus, effects on infection, 39, 44
Costs of rheumatoid arthritis, 827–833
 income losses, 830–832

medical, 829–830, 832
psychosocial, 832–833
CPPD crystals, *see* Calcium pyrophosphate dihydrate crystals
Crohn's disease
 bone scanning an, 235
 clinical abnormalities in, 235
 clinical associations with, 623, 625–626
 epidemiologic studies in, 628–629
 HLA-B27 and, 235–236
 nonenteric manifestations of, 234
 psoriasis and, 236
 quantitative sacroiliac scintigraphy in, 234–237
 radiologic abnormalities in, 235
 Reiter's syndrome and, 236
 sacroiliitis and, 234
CRVO, *see* Central retinal vein occlusion
Cryoglobulinemia, chrysotherapy in, 790
Cyclophosphamide for lupus nephritis, 570

D

D-penicillamine
 breast gigantism with, 167–168
 and rheumatoid arthritis, 110–112, 396
Danazol and arthritis, 493–494
Degenerative joint disease, synovial fluid lubricating ability in, 754–760
Dermatomyositis, nuclear antigens and, 804
Diabetes, carpal tunnel syndrome and, 221
Diffuse idiopathic skeletal hyperostosis, (DISH), 1–6
Diffuse proliferative glomerulonephritis, in systemic lupus erythematosus, 577–578
Diphosphonates, effects of in articular cartilage, 942–949
DISH, *see* Diffuse idiopathic skeletal hyperostosis
Disappearing carpal bones, *see* Idiopathic multicentric osteolysis
DJD, *see* Primary degenerative joint disease
DNA binding, in systemic lupus erythematosus, 552
DNA complexes, in systemic lupus erythematosus, 17–22
DNA structure
 analysis of, 407–413
 ethidium bromide in analysis of, 407–413
 hydroxyapatite chromatography in analysis of, 407–413
DNA-protein, rheumatoid factor and, 540
DNA/Anti-DNA complexes
 in systemic lupus erythematosus, 17–22
 sunburn and, 21
 trauma and, 21
DPGN, *see* Diffuse proliferative glomerulonephritis
Dysproteinemia, amyloid arthropathy in absence of, 587–588

E

Echovirus-associated polyarthritides, 978–981
Ehlers-Danlos syndrome, 545
Estrogen
 and systemic lupus erythematosus, 306
 and rheumatoid arthritis, 506–561
Experimental ferritin-induced arthritis, *see* Ferritin-induced arthritis
Extrinsic bronchial asthma, chrysotherapy in, 790

F

Factor B and rheumatoid arthritis, 567–568
Familial Mediterranean fever in children
 diagnosis of, 573
 treatment of, 573

Familial arthropathy, 429-437

see also Arthropathy

Familial lupus, 183-191

see also Systemic lupus erythematosus

Felty's syndrome

immune complexes in, 310-315

immunodiffusion studies in, 311-312

inhibition of marrow-granulocyte precursors in, 560

leukopenia and, 310

rheumatoid arthritis, comparison to, 310-315

ultracentrifugation studies in, 312-313

Femoral neck, buttressing of, 161-164, 869

Ferritin-induced arthritis

articular collagenous tissue changes in, 81-91

chronic inflammation in, 81-91

immunization protocol influence on severity of, 83

rheumatoid disease resemblance to, 90

Fibrinogen

half-life of, 334-345

heparin and, 345

systemic lupus erythematosus and, 343

turnover in progressive systemic sclerosis, 343-347

Fingers, congenital flexion contractures of, 429-437

Flexor tenosynovitis

betamethasone treatment for, 94

corticosteroid treatment for, 92-96

natural history of, 95

nonsurgical management of, 92-96

prednisolone treatment for, 94

in rheumatoid arthritis, 92-96

surgical management of, 92

triamcinolone treatment for, 94

FLMP, see Formylmethionyl-leucyl-phenylalanine

FMF, see Familial Mediterranean fever

Forestier's disease (ankylosing vertebral hyperostosis)

etiology of, 468

HLA antigens in, 467-472

HLA-B27 and, 468-471

origin of, 467

in Pima Indians, 467-472

race distribution in, 471

radiographic characteristics of, 467

Formylmethionyl-leucyl-phenylalanine, methyl ester of, 133-136

Frentizole, in systemic lupus erythematosus, 599

FS, see Felty's syndrome

FT, see Flexor tenosynovitis

Fulminant lupus erythematosus, C2 deficiency with, 28-35

G

Gastric mucosa, therapy for, 572

Giant cell arteritis

in blacks, 863

blind proximal temporal artery biopsy in, 780-784

corticosteroid therapy in, 365

diagnosis of, 780-784

occult, 565

polymyalgia rheumatica and, 780

race distribution in, 391-393

temporal arteriography in, 780-784

Glomerulonephritis

in polymyositis, 554

sicca syndrome and, 580

Glycosaminoglycan synthesis, effect of diphosphonate on, 942-949

Gold, see Chrysotherapy, Gold compounds

Gold compounds

distribution in guinea pig serum, 441-446

dosage schedules of, 168-169

efficacy of, 513-515

inhibition of, 133-136

levels in guinea pig serum, 441-446

monocytes and, 133-136

orally administered, 441-446

in psoriatic arthritis, 513-515

reactions to, 281

in rheumatoid arthritis, 513-515

toxicity of, 513-515

Gold salts, see Gold compounds

Gonococcal arthritis, diagnosis of, 572-573

Gout

carpal tunnel syndrome and, 221

colchicine treatment for, 731

multiple myeloma and, 150

polyarticular attacks and, 544

rheumatoid factor in, 544, 741-742

synovitis and, 544

H

Hand

primary degenerative joint disease of, 210-211, 215, 218

Kruskal-Wallis test for task differences with right and left, 214

pain in early diagnosis of lepra, 282-283

right and left differences, 218

structure and function of in industrial settings, 210-220

Hemarthrosis

anticoagulant therapy as cause of, 151

heparin relationship with, 740

in myeloma arthritis, 148-151

sodium warfarin relationship with, 740

Hemochromatosis, see Hemochromatotic arthropathy

Hemochromatotic arthropathy

mimicking rheumatoid arthritis, 844-848

phlebotomy as treatment for, 844, 848

Hemophilia

biochemical characteristics of, 141-142

clinical characteristics of, 137

proliferative synovitis in, 137-144

synovitis in, 137-144

Herpes zoster

clinical manifestations of, 799-800

in systemic lupus erythematosus, 798-802

systemic lupus erythematosus activity and, 800

treatment of systemic lupus erythematosus and, 800

Histocompatibility antigens, see HLA Antigens

Hip diseases, buttressing of femoral neck in, 161-164

HLA antigens

in ankylosing spondylitis, see Ankylosing spondylitis, HLA antigens and

in arthritis, 542, 885-888, 995-998

in black Americans, 892-894

and peripheral psoriatic arthritis, 72-76

in psoriasis vulgaris, 73

in spondylarthritis, 889-895

in systemic lupus erythematosus, 183-191

HLA-B7, ankylosing spondylitis associated with, 528-530

HLA-B8, rheumatoid arthritis and, 338

HLA-B27

ankylosing spondylitis and, 337, 528-530, 885

arthritis and, 542

associated arthritis, 885-888

in Crohn's disease, 235-236

Forestier's disease and, 467-472

HLA-C locus antigens, 885-888
in idiopathic ankylosing spondylitis, 889
inflammatory bowel disease and, 236
myasthenia gravis and, 337
race distribution and, 528
in Reiter's syndrome, 885, 889
in spondylarthritis, 889-895
HLA-BW38, peripheral psoriatic arthritis and, 72-75
HLA-C, arthritis and, 542
HLA-Cw1, in spondylarthritis, 889-895
HLA-Cw2, in spondylarthritis, 889-895
HLA-Dw3, rheumatoid arthritis and, 338
HLA-Dw4, and ankylosing spondylitis, 997
Homozygous C2 deficiency, with fulminant lupus erythematosus, 28-36
Horseradish peroxidase
extravascular localization of, 923-925
injection into rabbits, 918-929
ultrastructural cytochemistry after injections of, 921-925
Hyaluronate, prostaglandin E and the production of, 694-698
Hydralazine and systemic lupus erythematosus, 565-566
Hydroxychloroquine
for migrainous phenomena, 14
ophthalmologic safety of long-term use of, 588

I

IC, *see* Immune complexes
Identical twins, *see* Monozygotic twins
Idiopathic ankylosing spondylitis, HLA-B27 and, 889
Idiopathic Charcot arthropathy, 723-728
Idiopathic multicentric osteolysis
age of onset, 367
genetic predisposition to, 367
histopathology of, 372
nephropathy and, 372
origin of name of, 367
trauma, relationship to, 367
Immune complexes, *see also* DNA/Anti-DNA complexes
anti-antibody inhibition test for soluble, 639, 641-642
Lyme arthritis and, 564
in mixed connective tissue disease, 562-563
monocyte cytotoxicity and, 543-544
polymorphonuclear leukocytes, interaction with, 598
in rheumatoid arthritis, 107, 639-644
in sicca syndrome, 580
in systemic lupus erythematosus, 107, 539-540
Immune renal disease, 549
Immune synovitis, oophorectomy in, 560-561
Immunoglobulin
measurement of, 331-334
on MSU crystals, 353-361
in tophi, 353-361
Immunoglobulin aggregates, 516-527
Immunoglobulin synthesis, impaired by PBL, 51-57
Immunologic network, 853-862
chronic idiopathic disease and, 859
Immunology, 853-862
history of, 853-854
IMO, *see* Idiopathic multicentric osteolysis
Inflammatory bowel disease, HLA-B27 and, 236
Informed consent, validity of, 991-992
Intestinal bypass
arthritis after, 599, 605
postsurgical complications of, 599
Intratendon sheath corticosteroid treatment, 92-96
Ischemic necrosis

buttressing of femoral neck in, 161-162
management of, 606
in systemic lupus erythematosus, 606

J

Joint inflammation, relationship to immunologically induced changes in ACT, 86
JRA, *see* Juvenile rheumatoid arthritis
Juvenile rheumatoid arthritis (JRA)
adoption frequency among patients with, 231-232
age at onset of, 230
American and European, contrast of, 699-703
amyloidosis of, 699-703, 867-868
causes of, 229-233
clinical management of, 129-132
corticosteroid therapy in, 131
etiology of, 229
familial arthropathy contrasted with, 433
fingerstick method for measurement of plasma salicylate in, 129-132
genetic predisposition to, 229
hand in, 561-562
parents' marital status of patients with, 231, 233
psychosocial factors in, 229-233
rheumatoid arthritis distinguished from, 231
rheumatoid factor in, 579
SAA protein levels in, 699-703
salicylate and, 129-132
stress factors and, 232
surgical management of, 401-406
total hip replacement in, 401-406

K

Klinefelter's syndrome
monozygotic twins with, 306-309
myasthenia gravis and, 306-309
systemic lupus erythematosus and, 306-309
Knee
diagnostic arthroscopy of, 541
osteoarthritis of, 556
radiographic survey of, 395-396
Knee joint, Tc-pertechnetate uptake in, 348, 352
Kruskal-Wallis test, 214

L

Lactic acid, of synovial fluid, 774-779
Latex fixation rheumatoid factor test, 224, 226
Legionnaires' disease, in patient with systemic lupus erythematosus, 975-977
Lepra, hand pain in early diagnosis of, 282-283
Leukocyte functions
estradiol effects on, 324
pregnancy serum effects on, 316-325
Leukopenia
colchicine as cause of, 733
of Felty's syndrome, 310
in systemic lupus erythematosus, 504
Levamisole, in rheumatoid arthritis, 326-329, 589-590
see also Systemic lupus erythematosus
Lupus nephritis, 21
azathioprine in, 570

cyclophosphamide in, 570
in systemic lupus erythematosus, 41, 43

Lyme arthritis
immune complexes and, 564
juvenile rheumatoid arthritis contrasted with, 167

Lymphocyte count
disease activity, relationship with, 300
lymphopenia and, 297-299

Lymphocytes
B in NZB mice, 551
monocyte cytotoxicity and, 543-544
rosette formation and propranolol, 767-774
scleroderma and, 423

Lymphocytotoxic antibodies, in systemic lupus erythematosus, 189-190

Lymphoma, in Sjögren's syndrome, 585

Lymphopenia
diagnostic significance of, 301
lymphocyte count and, 297-299
prognostic significance of, 301-303
in systemic lupus erythematosus, 295-305

M

Macroglobulinemia, chrysotherapy in, 790

Marrow aplasia, colchicine-induced, 731-736

MCTD, *see* Mixed connective tissue disease

Membrane attack complex, 177-182
polymorphonuclear leukocytes and, 180
in systemic lupus erythematosus, 179

Migrainous phenomena
description of, 8-9
electroencephalograph of patients with, 12-13
fortification specters in, 8-9
scotomas in, 9
in systemic lupus erythematosus, 7-16
spinal fluid analysis of patients with, 12-13
treatment for, 13-14
aspirin, 14
hydroxychloroquin, 14
prednisone, 14
visual hallucinations in, 7-9

Mitogens, cell response to in NZ mice, 199-200

Mixed connective tissue disease (MCTD), 497-503
arthritis of, 497-503
autoimmune anemia in, 995-997
circulating immune complexes in, 562-563
clinical features of, 497-503
gastrointestinal systemic sclerosis in, 811-819
genetic predisposition to, 709-714
histologic evaluation of, 593
history of, 811
myelitis in, 982-986
neurologic involvement in, 982-986
pattern of disease presentation, 498
prognosis of, 985
rheumatoid arthritis and, 497-498, 502
serologic description of, 982
in siblings, 709-714
systemic sclerosis in, 811-819
thrombopenia in, 995-997
transverse myelitis in, 982-986

Mixed cryoglobulinemia, synovial fluid in, 740-741

Mixed tissue disease, *see* Mixed connective tissue disease

MNC, *see* Monocytes

MON, *see* Multicentric osteolysis with nephropathy

Monocyte cytotoxicity, effect of immune complex on, 543-544

Monocytes
gold compound inhibition and, 133-136
PMN and, 133-136

Monosodium urate crystals
agglutination of, 354, 356-360
cellular interaction with, 558, 896-903
immunoglobulin on, 353-361

Monzygotic twins
discordant for myasthenia gravis, 306-309
discordant for systemic lupus erythematosus, 306-309
Klinefelter's syndrome in, 306-309

MSU crystals, *see* Monosodium urate crystals

Multicentric osteolysis with nephropathy, 372, 375

Multiple myeloma
amyloid arthritis and, 148
gout and, 150
rheumatic manifestations of, 149
septic arthritis and, 150

Muscle disease
in polymyositis/dermatomyositis, 62-71
in progressive systemic sclerosis, 62-71

Myasthenia gravis
HLA-B27 and, 337
Klinefelter's syndrome and, 306-309
monozygotic twins and, 306-309
systemic lupus erythematosus and, 306-309
thymus, role of, 492-493

Myelitis, transverse in mixed connective tissue disease, 982-986

Myeloma arthritis, hemarthrosis in, 148-151

Myeloma
rheumatoid arthritis and, 263
systemic lupus erythematosus and, 260-265
symptoms of, 262

Myopathy
complicated, 64, 66
diagnostic considerations in, 62-71
in scleroderma, 62-71
simple, 64
therapeutic considerations in, 64, 69-70

Myxedema, carpal tunnel syndrome and, 221, 223

N

Nafoxidine, 414-417
autoimmunity and, 414-417
DNA antibodies and, 415
New Zealand mice and, 414-417
proteinuria and, 415

Nephritis
and alternative complement pathway, 28-35
in systemic lupus erythematosus, 41, 43

Nephropathy, in polymyositis, 554

Neutral proteoglycanase, forms of, 588

Neutropenia
kinetics in, 507
serum fractionation studies in, 508-510
in systemic lupus erythematosus, 504-512

New Zealand mice
autoimmune diseases in, 51, 850
cell effects of mitogens in, 199
concanavalin, effects on, 204-209
foreign antigens, response to, 200
lymphocyte function, effect on, 196-203
mitogens, response to, 199-200
nafoxidine and, 414-417
suppressor lymphocyte in aged, 578

therapeutic studies in, 204–209
thymosin in, 196–203
Nuclear antigens
cellular localization of, 805–806
clinical features of, 806–807
connective tissue diseases and, 803–810
dermatomyositis and, 804
physicochemical properties of, 806
sicca syndrome and, 810
systemic lupus erythematosus and, 804
NZB/NZW mice, *see* New Zealand mice

O

Oncornavirus C, *see* Type C virus
Oophorectomy, in immune synovitis, 560–561

Oral mucosal ulceration
clinical features of, 58–60
corticosteroid treatment for, 60
hard palate involvement in, 59
renal disease associated with, 59
serologic features of, 58–59
in systemic lupus erythematosus, 58–61

Osteoarthritis
articular cartilage collagenase activity and, 761–766
buttressing of femoral neck in, 161–164, 869
cartilage phosphatases in, 597
corticosteroid therapy in, 556
features of, 163–164
Rumalon R as treatment for, 494–496
sampling problems in, 763
sex hormone effects in, 586–587
synovial lubrication in, 758

Osteomalacia
atypical axial, 715–722
causes of, 715

Osteopenia, glucocorticoid-induced in rabbits, 581

Osteophytes, rheumatoid arthritis diffuse idiopathic skeletal hyperostosis and, 4

Osteoporosis
of the knee, 992–993
and rheumatoid arthritis diffuse idiopathic skeletal hyperostosis, 4

P

Pancytopenia, caused by colchicine, 735

Paravertebral ossification, vertebral sarcoidosis with, 271–276

Patellar articular cartilage, horizontal splitting in, 669–674

Pemphigus, chrysotherapy in, 790

Penicillamine therapy, *see* D-penicillamine

Peptidoglycans, 534–537

Pericarditis, corticosteroid therapy in, 391

Peripheral blood leukocytes, in systemic lupus erythematosus, 177–182

Peripheral blood lymphocytes

anti-DNA synthesis by, 582

calcium ionophore and, 326–329

Con-A and, 326–329

immunoglobulin synthesis impaired by, 51–57

PHA and, 326–329

in rheumatoid arthritis, 326–329, 593–594

in systemic lupus erythematosus, 51–57, 326–329

Peripheral blood neutrophils

antiimmunoglobulin effects on, 598

functional responses of, 598

PGC, *see* Proteoglycan aggregates

PHA, *see* Phytohemagglutinin

Phagocytosis, kinetic studies of, 107–113

Phytohemagglutinin

levamisole and, 326, 329

lymphocyte response to, 326–329

rheumatoid arthritis and, 326–329

systemic lupus erythematosus and, 326–329

Pima Indians, Forestier's disease and, 467–472

Plasma salicylate, measurement of in juvenile rheumatoid arthritis, 129–132

Platelets, in synovial space, 994–995

PM/DM, *see* Scleroderma

PMN leukocytes, *see* Polymorphonuclear leukocytes

Pokeweed mitogen, as immunoglobulin inducer, 51–54

Polyarteritis

abdominal syndromes in, 606

arthropathy associated with, 281–282

corticosteroid therapy in, 365

Polyarthritis

echovirus-associated, 978–981

gout and, 544

seronegative, *see* Seronegative polyarthritis

Polymorphonuclear (PMN) leukocytes

chemotactic responses of, 133–136

depletion in systemic lupus erythematosus, 504–512

functions

phagocytosis and, 316

pregnancy serum effects on, 316–325

immune complexes, interaction with, 598

microtubule control of, 594

phagocytic rates of, 109

serum independent particle uptake by, 107–113

Polymyalgia rheumatica, carpal tunnel syndrome and, 221–223, 865

Polymyositis

azathioprine treatment in, 548

glomerulonephritis in, 554

nephropathy in, 554

Polymyositis/dermatomyositis, *see* Scleroderma

Prednisolone

for flexor tenosynovitis, 94

for migrainous phenomena, 14

Pregnancy serum

phagocytosis and, 316

polymorphonuclear leukocyte functions and, 316–325

Primary degenerative joint disease of hand, 210–211, 215, 218

clinical patterns of, 210

inheritability of, 210

pathogenesis, 210–211

Progressive systemic sclerosis, *see* Scleroderma

Proliferative synovitis, *see* Synovitis

Propranolol

effects on lymphocyte rosette formation, 767–774

effects on rheumatoid factor, 118

plant mitogen response and, 767–774

Prostaglandin E, hyaluronate production and, 694–698

Prostaglandins

articular cartilage metabolism and, 909–917

in rheumatoid arthritis, 909

Proteoglycan

analysis of, 579–580

arthritic effect on biosynthesis of, 678

in articular cartilage, 675–680

Proteoglycan aggregates, 453–460, 942–949

diphosphonate effect on, 942–949

in potassium buffer, 456

in sodium buffer, 455–456

Pseudogout, colchicine treatment of, 596

Psoriasis, *see* Psoriatic arthritis

Psoriatic arthritis

- ankylosing spondylitis and, 628
- axial, 74
- chrysotherapy in, 513-515
- definitions of, 620
- deforming group of, 621
- distal joint involvement in, 620-621
- epidemiologic studies in, 628-629
- gold reactions in, 513-515
- indistinguishable group of, 621-622
- peripheral, 72-76
- Reiter's disease and, 622, 624
- seronegative polyarthritis and, 619-622

PSS, *see* Progressive systemic sclerosis

Purine nucleoside phosphorylase, deficiency of, 603-604

PWM, *see* Pokeweed mitogen

Pyarthrosis, acute hematogenous osteomyelitis progressing to, 968-971

Pyrophosphate

- activity of the synovial fluid, 447-452
- chondrocalcinosis and, 447-452

Q

QSS, *see* Quantitative sacroiliac scintigraphy

Quantitative sacroiliac scintigraphy

- antiinflammatory drugs, influence on, 236
- in Crohn's disease, 234-237

R

RA, *see* Rheumatoid arthritis

Radioimmunoassay

- anticollagen antibodies in rheumatoid arthritis demonstrated by, 243-248
- type C virus and, 267

Reflex sympathetic dystrophy syndrome, 838

Regional migratory osteoporosis, 834-838

- diagnosis of, 836
- reflex dystrophy syndrome contrasted with, 838
- treatment of, 838

Reiter's syndrome

- clinical associations with, 622, 624
- communicability of, 283-284
- epidemiologic studies in, 628
- HLA-B27 and, 885, 889
- HLA-C and, 886
- natural history of, 548-549
- probability theory and, 863-864
- psoriatic arthritis and, 622, 624
- seronegative polyarthritis and, 622, 624, 628

Renal transplantation, joint effusions after, 575

RF, *see* Rheumatoid factor

RF PFC, *see* Rheumatoid factor plaque-forming cell

Rheumatic diseases, *see also* specific disease names

- ambulatory patients and, 377-382
 - classification of, 378
 - frequency of, 380-382
 - mortality versus disability in, 379-380
 - national health survey of, 377-378
 - severity of, 380-382
 - terminology in, 378
- Rheumatic fever, acute**
- causes of, 652
 - clinical manifestations of, 653
- genetic studies in, 652**
- hereditary factors in, 653-655**
- HLA antigens in, 652-656**
- Rheumatoid arthritis**
- analgetics for, 564
 - ankylosing spondylitis with, 383-389
 - anti-antibody inhibition test in, 639, 641-642
 - anticollagen antibodies in, 243-248
 - antiglobulins in, 438-440
 - antiimmunoglobulins and, 120-128
 - antinuclear antibodies in, 645-651
 - articular collagenous tissues in, 516-527
 - articular involvement in, 577
 - azathioprine therapy in, 539
 - bacterial infections, susceptibility to, 111
 - buttressing of femoral neck in, 161-163
 - C4 in, 567-568
 - C-reactive protein in, 491
 - calcium ionophore and, 326-329
 - carpal tunnel syndrome and, 221-223
 - cervical disc disease in, 737-739
 - chrysotherapy in, 441, 513-515
 - circulating antibodies in, 249
 - collagen as autoantigen in, 243
 - Con-A and, 326-329
 - corticosteroid treatment of, 92-96, 110, 112
 - cost of, 827-833
 - cytotoxicity in, 601-602
 - diagnostic criteria for, 383
 - diffuse idiopathic skeletal hyperostosis and, 1-6
 - D-penicillamine and, 110, 112, 396
 - drug efficacy in, 171-172
 - estrogen and, 560-561
 - etiology of, 531-538
 - factor B in, 567-568
 - Felty's syndrome, comparison with, 310-315
 - gold therapy in, 441, 513-515
 - heterophile antibodies in, 634-638
 - HLA-B8 and, 338
 - HLA-Dw3 and, 338
 - HLA-Dw4 and, 558, 690
 - idiopathic hand flexor tenosynovitis and, 92-96
 - immune complexes in, 310-315, 639-644
 - immunodiffusion studies in, 311-312
 - immunoglobulin aggregates in, 516-527
 - immunoglobulins in, 331-334
 - immunologic features of, 120
 - immunopathologic studies of, 249-255
 - infectious etiology of, 531-538
 - influenza antibodies in, 239
 - inhibition experiments in, 245-246
 - intraperitoneal steroids in, 280
 - joint fluids in, 245
 - levamisole therapy in, 326-329, 589-590
 - light chains in, 438-440
 - lymphoblastoid cell lines in, 582-583
 - lymphocyte cell synthesis in, 330-336
 - lymphocyte response inhibition in, 171-172
 - lymphocytes to virus antigens in, 238-242
 - measles antibodies in, 239
 - mitogens and, 238, 241
 - mixed connective tissue disease and, 497-498, 502
 - monocyte antibody-dependent cell-mediated cytotoxicity in, 601-602
 - mycoplasma and, 533
 - nuclear antigens and, 540-541
 - ocular manifestations of, 595
 - oophorectomy and, 560-561

pathogenesis of, 238, 252–253
peptidoglycans and, 534–537
peripheral blood lymphocytes in, 593–594
PHA and, 326–329
phagocytosis and, 107–113
phytohemagglutinin and, 238
polymorphonuclear leukocytes and, 107–113
proteoglycan depletion of cartilage matrix in, 909
radiographic abnormalities of, 1–5
radioimmunoassay in, 243–248
rheumatoid factor in, 330, 332, 438, 645–651
robust type with diffuse idiopathic skeletal hyperostosis, 1
rubella and, 240
serologic studies in, 109–110
serum antiimmunoglobulins in, 120–128
shoulder swelling in, 145–147
subacromial bursitis, secondary to, 145–147
subacute bacterial endocarditis and, 438–440
susceptibility to, 556
synovial cells susceptibility to ADCC, 97–105
synovial fluids in, 243–248, 249–255
synovial inflammation in, 97, 556
synovitis and, 330, 438, 560–561
tear lysozyme increase in, 595
tenosynovitis and, 92–96
ultracentrifugation studies in, 312–313
viral infections and, 238, 533–534
virus antigens in, 238–242
wrist involvement in, 555

Rheumatoid factor plaque-forming cell (RF PFC), effect of cyclic nucleotides on, 118

Rheumatoid factor (RF)
 antinear antibodies and, 645–651
 assay, automated, 224–228
 benign rheumatoid nodules, and, 930–934
 complement-fixing in juvenile rheumatoid arthritis, 579
 cyclic nucleotides effect on, 118
 DNA-protein and, 540
 drug effects on, 114–119
 gout and, 544
 hemolytic plaque-forming assay for, 820–821
 HLA-Dw4 and, 690–693
 infection relationship to in rheumatoid arthritis, 111
 in juvenile rheumatoid arthritis, 579, 935–941
 latex agglutination test for, 224, 226
 lymphocyte reaction in healthy women with, 690–693
 lymphocyte release of, 115
 and phagocytic performance interference, 111
 in plaque-forming cell assay, 114–119
 propranolol effect on, 118
 in rheumatoid arthritis, 111, 226–228, 645–651
 relative reactivities of in serum and cells, 820–826

Rheumatoid plaque-forming cell, 114–119

Rheumatoid synovial cells
 antibody against, 102
 antibody-dependent cell-mediated cytotoxicity (ADCC), susceptibility to, 97–105
 susceptibility to lysis, 100
 viral-like particles in, 559

Rheumatoid synovitis, *see also* Synovitis
 analgetics for, 564

Rheumatoid vasculitis, ankylosing spondylitis with, 383–389

Ribonuclease sensitive antigen, 608

RMO, *see* Regional migratory osteoporosis

RS, *see* Reiter's syndrome

Rumalon R, for osteoarthritis, 494–496

S

Salicylates, *see also* Aspirin
 in juvenile rheumatoid arthritis, 129–132
 measurement of concentration of, 129–132

Sarcoidosis
 corticosteroid therapy in, 271
 course of, 275
 osseous involvement in, 271
 paravertebral ossification and, 271–276
 suppressor cell function in, 561

Satellite arthritis clinic, 727–730
 advantages of, 728–729
 problems of, 729

SBE, *see* Subacute bacterial endocarditis

Scleroderma
 cardiomyopathy in, 609–611
 clinical criteria for, 65, 576–577
 collagen in, 418–428
 corticosteroid therapy in, 69
 definition of, 62–63
 electromyography and, 993–994
 electron microscopy and, 421–423
 fibrinogen turnover in, 343–347
 gastrointestinal symptoms in, 811–819
 histology of, 421
 immunofluorescence and, 423
 lymphocytes and, 423
 and mixed connective tissue disease, 576, 811–819
 model for, 557
 muscle disease and, 62–71
 myopathies and, 64, 66
 renal crisis in, 600–601
 stages in development of, 418
 vascular abnormalities in, 346

SCN, *see* Subcutaneous nodule

SD, *see* Scleroderma

Septic arthritis
 diagnostic aid in, 774–779
 in multiple myeloma, 150
 radiographic features in, 998–999
 synovial fluid lactic acid in, 774–779

Septic discitis, 574–575

Septic synovitis, acute hematogenous osteomyelitis progressing to, 968–971

Seronegative polyarthritis
 Behcet's syndrome and, 623, 626
 clinical association with, 622–626
 concept of, 622–630
 Crohn's disease and, 623, 625–626, 628–629
 epidemiologic studies in, 627–629
 familial aggregation of, 626–627
 histocompatibility antigens and, 629
 psoriatic arthritis and, 619–622, 624, 628
 Reiter's disease and, 622, 624, 628
 ulcerative colitis and, 622–625, 629
 Whipple's disease and, 623–624

Seronegative spondarthritis, *see* Seronegative polyarthritis

Serum antiimmunoglobulins
 in normal individuals, 120–128
 in osteoarthritis, 120–128
 in rheumatoid arthritis, 120–128
 reactive with human and rabbit IgG, 120–128
 in rheumatic fever, 120–128

Shoulder swelling, in rheumatoid arthritis, 147–149

Sicca syndrome
 B-lymphocyte antigens in, 580–581
 circulating immune complexes in, 580
 glomerulonephritis in, 580
 nuclear antigens and, 810

Sickle cell disease
 systemic lupus erythematosus and, 862–863
 uric acid overproduction in, 553–554

Sjögren's syndrome
 age of onset of, 385
 chrysotherapy in, 790

- definition of, 584
 HLA-B8 and, 337-342
 HLA-Dw3 and, 337-342
 lymphoma in, 585
 severity of, 340-341
 sex distribution of, 385
- SLE, see Systemic lupus erythematosus**
- SLE-PBL, see Peripheral blood lymphocytes in systemic lupus erythematosus**
- Sodium warfarin and hemarthrosis, 740
- Spinal pseudoarthrosis, 485-490
- Spondylarthritis**
- HLA-B27 in, 889
 - HLA-Cwl and, 889-895
 - HLA-Cw2 in, 889-895
- Steroids, see Corticosteroids**
- Subacromial bursitis, rheumatoid arthritis secondary to, 145-147
- Subacute bacterial endocarditis**
- antiglobulins in, 438-440
 - light chains in, 438-440
 - rheumatoid arthritis and, 438-440
- Subcutaneous nodules**
- in children without juvenile rheumatoid arthritis, 930
 - clinical significance in rheumatoid arthritis, 589
 - hemochromatosis and, 844-848
- Subperiosteal bone apposition, see Buttressing**
- Sulfanilamidoindazole arthritis, 681-689
- Suppressor lymphocyte, immunodeficiency associated with in mice, 578**
- Synovial cells**
- growth kinetics of, 461-466
 - viral-like particles in rheumatoid, 559
- Synovial fluid cells, in systemic lupus erythematosus, 590**
- Synovial fluid**
- boundary lubricating ability of, 754-760
 - in degenerative joint disease, 754-760
 - gonococcal arthritis and, 775-776
 - hydroxyapatite crystals in, 563
 - lactic acid of, 774-779
 - in mixed cryoglobulinemia, 740-741
 - platelets in, 607-608
 - septic arthritis and, 774-779
- Synovitis, see also Rheumatoid synovitis**
- analgetics for, 564
 - biochemical observations of, 137-144
 - gout and, 544
 - in hemophilia, 137-144
 - immunopathology of, 97
 - morphologic observations of, 137-144
 - oophorectomy in, 560-561
 - proliferative, 137-144
 - splinter-induced, 278
- Systemic lupus erythematosus (SLE)**
- abdominal syndromes in, 606
 - acetylation phenotypes, distribution in, 192-195
 - active urinary sediment effect on infection in, 42
 - acute pericarditis in, 972
 - age distribution in, 473-479
 - androgenic status of males with, 665-668
 - anti-DNA antibodies in, 45-50, 289-293, 543, 602, 950
 - anti-DNA complexes in, 17-22, 24-25
 - anti-DNA synthesis in, 582
 - antibodies
 - antilymphocyte in, 23-27, 289
 - antinuclear in, 55, 186, 590-591
 - antipolynucleotide and, 23-27
 - antiviral in, 23-27, 51
 - to histone in, 556-557
 - to neuronal cells in, 546
- ARA Preliminary Criteria for Classification of, Suggested revision of, 602**
- autoimmune diseases and, 51
- autoimmune neutropenia in, 504-512
- azathioprine in, 39-40
- C-reactive protein elevations in, 605
- C2 deficiency and, 28-35
- C3 deficiency and, 40-42
- C3 serum levels in, 178, 602
- cardiovascular complications of, 972-974
- causes of, 266
- cellular antigen preparations in, 873-879
- central nervous system dysfunction in, 289-294
- cerebral involvement in, 597-598
- in children, 599-600
- clinically quiescent, 559
- C1q-sepharose eluates characterization in, 20
- co-culture experiments in, 54-55
- complement fixation reactivities in, 873
- complement, role in, 177
- constrictive pericarditis in, 972-974
- corticosteroid therapy, 39, 112, 262-263
- central retinal vein occlusion in, 839-843
- disease activity in, 539-540, 568-569
- DNA/anti-DNA complexes in, 17-22
- DNA binding and, 552
- DNA complexes in, 17-22
- DNA structure in, 407
- diffuse proliferative glomerulonephritis and, 577-578
- drug-induced, 192-194, 556-557
- estrogen metabolism in, 306
- female predominance in, 849-852
- fever in, 594-595
- fibrinogen in, 343
- Frentizole therapy in, 599
- genetic implications of antibodies in, 23-27
- genetic information in tissues of, 880-884
- genetic predisposition to, 183-191, 306, 586
- gross splenomegaly in, 866
- herpes zoster in, 798-802
- histone antibodies in, 556-557
- HLA profiles in, 183-191
- hormonal factors in, 665-668
- household contact and antibodies in, 24-25
- hydralazine effects in, 565-566
- immune complexes in, 107, 539-540
- immune functions in, 657-664
- immunoglobulin level in, 27
- immunologic sex differences in, 849-852
- immunoperoxidase staining of choroid plexus in, 547
- infection
 - as cause of death in, 37
 - frequency in, 37-44
- influenza antibodies in, 25
- inhibition of natural killing of tumor cell line in, 592
- ischemic necrosis of bone in, 606
- kidney disease in, 578-579
- Klinefelter's syndrome and, 306-309
- laboratory personnel, immune reactivity of, 587
- Legionnaires' disease in, 975-977
- leukocyte counts and effect on infection in, 41
- leukopenia in, 504
- lupus nephritis, effect on infection in, 41-43
- lymphocyte counts in, 297-299
- lymphocytotoxic antibodies in, 189-190, 560
- lymphocytotoxicity of cerebrospinal fluid in, 603
- lymphopenia in, 295-305
- males with, 665-668
- manifestations of, 8-11
- measles antibody in, 25
- membrane attack complex and, 177-182
- migrainous phenomena in, 7-16
- monocytotoxic antibodies in, 170-171

monozygotic twins discordant for, 306–309
mortality statistics in, 473–479
myasthenia gravis and, 306–309
myeloma and, 260–265
nephritis in, *see* Lupus nephritis
neurologic manifestations in association with migrainous phenomena, 9–13
neuropsychiatric manifestations of, 289–294
neutropenia in, 504–512
neutrophilic inclusions in, 566
nuclear antigens and, 804
ocular disease in, 839–843
oral mucosal ulceration in, 58–61
oncornaviruses and, 266–270, 584, 880–884
pathogenesis of, 295, 306, 480–484, 657, 880, 950
pericarditis in, 972–974
peripheral blood leukocytes in, 177–182
peripheral blood lymphocytes in, 582
phagocytosis and, 107–113
plasmapheresis in, 567
pokeweed mitogen-stimulated cultures and, 51–56
polymorphonuclear leukocytes and, 107–113, 180
race distribution in, 473–479
renal disease activity in, 574
reticuloendothelial receptor function in, 563
serologic studies in, 109–110, 189, 289–294
serologically active, 559
sex distribution in, 306, 473–479, 665, 849–852
sex effects on, 480–484
sex hormones in, 306–309
sickle cell disease and, 862–863
suppressor macrophages in, 600
symptomatic myasthenia gravis and, 306–309
symptoms of, 262
synergy of sex and race in, 478, 480
synovial fluid cells in, 590
T cell dysfunction in, 56
T cell suppressor function in, 657–664
T gamma cells, decreased levels of in, 553
testosterone levels in, 307–308
thymus, role of in, 492–493
treatment decisions in, 601
type C oncornavirus-related genetic information in, 880–884
type C viruses and, 266–270, 584
uremia and effect on infection in, 41–43
urinary prostaglandin E in, 570
vascular dysfunction in as cause of migrainous phenomena, 16
viral etiology of, 880
virus antigen preparations in, 873–879
Westergren erythrocyte sedimentation rate effect on infection in, 40–41
Systemic sclerosis, *see* Scleroderma

T

T cell, in systemic lupus erythematosus, 56, 553, 657–664
Temporal arteriography, 780–784
Temporal arteritis, 362–366
Tenosynovitis
 carpal tunnel syndrome and, 223
 hemochromatosis and, 844–848
Thalassemia minor, aseptic necrosis and, 280
THR, *see* Total hip replacement
Thrombocytopenia, caused by colchicine, 733
Thrombopenia, in mixed connective tissue disease, 995–997
Thymosin treatment
 antibodies to, 198–199

effect on cells, 199
in New Zealand mice, 196–203
Tophi, immunoglobulins in, 353–361
Total hip replacement (THR)
 ambulatory status after, 403
 complications following, 404–405
 indications for, 401–406
 in juvenile rheumatoid arthritis, 401–406
 motivation of patient, importance of, 404
 physical therapy following, 404
 value of, 401–406
Transverse myelitis, in mixed connective tissue disease, 982–986
Traumatic arthritis
 fat droplets in synovial fluid, 76–80
 synovial fluid leukocytosis in, 76–80
Triamcinolone for flexor tenosynovitis, 94
Type C virus
 characteristics of, 266
 detection of, 267
 molecular hybridization as test for, 267
 radioimmunoassay for, 267
 systemic lupus erythematosus and, 266–270

U

Ulceration, oral mucosal in systemic lupus erythematosus, 58–61
Ulcerative colitis
 clinical associations with, 622–625
 epidemiologic studies in, 629
Urate solubility
 buffer cation effect on, 455–456
 enhancement of by connective tissue, 453–460
 gout and, 453
 potassium buffer and, 456
 proteoglycan aggregates effect on, 453–460
 sodium buffer and, 456
Uremia and systemic lupus erythematosus, 41, 43
Urinary sediment, effect on infection in systemic lupus erythematosus, 42

V

Vertebral ankylosing hyperostosis, *see* Forestier's disease
Vertebral sarcoidosis, paravertebral ossification and, 271–276
Vitamin D, and osteomalacia, 715, 722

W

Wegener's granulomatosis, parotid nodules in, 864–865
Westergren erythrocyte sedimentation rate, effect on infection in systemic lupus erythematosus, 40–41
Whipple's disease, clinical associations with, 623–624
Wrist, *see also* Carpal tunnel syndrome
 in rheumatoid arthritis, 555
 surgical stabilization of rheumatoid, 555

Y

Yersinia infection
 antiepithelial antibodies in, 904–908
 clinical manifestations of, 907
 gammaglobulin concentrations in, 905
 humoral immune stimulation in, 904–908
 sex distribution in, 907

8